Trial Outcomes & Findings for Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors (NCT NCT01966445)
NCT ID: NCT01966445
Last Updated: 2019-07-01
Results Overview
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; and left ventricular ejection fraction (LVEF) meeting stopping criteria. AEs were collected in All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
29 participants
Primary outcome timeframe
Median of 6.143 weeks of drug exposure
Results posted on
2019-07-01
Participant Flow
This is a Phase 1 study of anti-human epidermal growth factor receptor 3 (HER3) antibody, GSK2849330 in participants with advanced solid tumors expressing HER3. The study was conducted in 2 parts-Part1 (dose escalation) and Part2 (dose expansion). The starting dose in Part1 was 1.4 milligrams per kilogram (mg/kg) GSK2849330 given weekly for 28 days
A total of 29 participants were randomized. The study was conducted in three countries. Participants in the GSK2849330 30 mg/kg weekly arm were not double counted with any other Arm.
Participant milestones
| Measure |
Part1: GSK2849330 1.4 mg/kg Weekly
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
Part1: GSK2849330 3 mg/kg Every 2 Weeks
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
Part1: GSK2849330 3 mg/kg Weekly
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
Part1: GSK2849330 10 mg/kg Every 2 Weeks
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
Part1: GSK2849330 30 mg/kg Every 2 Weeks
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
Part1: GSK2849330 30 mg/kg Weekly
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
Part2: GSK2849330 30 mg/kg Weekly
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
|---|---|---|---|---|---|---|---|
|
Part1 (Median Exposure of 6.143 Weeks)
STARTED
|
1
|
3
|
2
|
5
|
4
|
5
|
0
|
|
Part1 (Median Exposure of 6.143 Weeks)
COMPLETED
|
1
|
1
|
1
|
2
|
1
|
4
|
0
|
|
Part1 (Median Exposure of 6.143 Weeks)
NOT COMPLETED
|
0
|
2
|
1
|
3
|
3
|
1
|
0
|
|
Part2 (Median Exposure of 7.143 Weeks)
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
|
Part2 (Median Exposure of 7.143 Weeks)
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
|
Part2 (Median Exposure of 7.143 Weeks)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
Reasons for withdrawal
| Measure |
Part1: GSK2849330 1.4 mg/kg Weekly
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
Part1: GSK2849330 3 mg/kg Every 2 Weeks
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
Part1: GSK2849330 3 mg/kg Weekly
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
Part1: GSK2849330 10 mg/kg Every 2 Weeks
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
Part1: GSK2849330 30 mg/kg Every 2 Weeks
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
Part1: GSK2849330 30 mg/kg Weekly
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
Part2: GSK2849330 30 mg/kg Weekly
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
|---|---|---|---|---|---|---|---|
|
Part1 (Median Exposure of 6.143 Weeks)
Lost to Follow-up
|
0
|
0
|
0
|
2
|
0
|
1
|
0
|
|
Part1 (Median Exposure of 6.143 Weeks)
Physician Decision
|
0
|
1
|
0
|
1
|
1
|
0
|
0
|
|
Part1 (Median Exposure of 6.143 Weeks)
Withdrawal by Subject
|
0
|
1
|
1
|
0
|
2
|
0
|
0
|
|
Part2 (Median Exposure of 7.143 Weeks)
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
Part2 (Median Exposure of 7.143 Weeks)
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
Baseline Characteristics
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Baseline characteristics by cohort
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
Total
n=29 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
63.0 Years
STANDARD_DEVIATION NA • n=5 Participants
|
62.3 Years
STANDARD_DEVIATION 4.04 • n=7 Participants
|
46.0 Years
STANDARD_DEVIATION 21.21 • n=5 Participants
|
66.2 Years
STANDARD_DEVIATION 7.19 • n=4 Participants
|
58.3 Years
STANDARD_DEVIATION 8.73 • n=21 Participants
|
62.5 Years
STANDARD_DEVIATION 11.65 • n=8 Participants
|
61.4 Years
STANDARD_DEVIATION 10.91 • n=8 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
5 Participants
n=8 Participants
|
13 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
9 Participants
n=8 Participants
|
16 Participants
n=8 Participants
|
|
Race/Ethnicity, Customized
Race customized · Asian-Central/South Asian Heritage
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
|
Race/Ethnicity, Customized
Race customized · White
|
1 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
13 Participants
n=8 Participants
|
28 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: Median of 6.143 weeks of drug exposurePopulation: All Treated Population
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; and left ventricular ejection fraction (LVEF) meeting stopping criteria. AEs were collected in All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Parts 1 and 2
AEs
|
1 Participants
|
3 Participants
|
2 Participants
|
5 Participants
|
4 Participants
|
14 Participants
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Parts 1 and 2
SAEs
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Up to 28 daysPopulation: All Treated Population
An event was considered a DLT if it occured within the first 4 weeks (28 days) of treatment, and met one of the following criteria unless it could be established that the event was unrelated to treatment: Grade 3 or greater non-hematologic toxicity; Grade 4 neutropenia lasting \>5 days; Febrile neutropenia, of any grade or duration; Grade 4 thrombocytopenia, or Grade 3 thrombocytopenia associated with bleeding; Alanine aminotransferase (ALT) \>3 times upper limit of normal (ULN) with bilirubin \>2 times ULN; Any Grade 2 or greater toxicity that in the judgment of the investigator and GlaxoSmithKline (GSK) Medical Monitor, would be considered dose-limiting; Grade 3 or greater decrease in LVEF. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Dose-limiting Toxicities (DLTs)-Parts 1 and 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline and median of 6.143 weeks of drug exposurePopulation: All Treated Population. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles).
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Total bil), calcium, creatinine, gamma glutamyl transferase (GGT), glucose, potassium, magnesium, sodium, phosphorus, uric acid. Laboratory parameters were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. Data for worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Albumin; any Grade increase; n=1,3,2,5,4,14
|
1 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
6 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Albumin; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Albumin; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
ALP; any grade increase; n=1,3,2,5,4,14
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
7 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
ALP; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
ALP; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
ALT; any Grade increase; n=1,3,2,5,4,14
|
0 Participants
|
2 Participants
|
0 Participants
|
2 Participants
|
3 Participants
|
6 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
ALT; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
ALT; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
AST; any Grade increase; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
5 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
AST; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
AST; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Total bil; any Grade increase; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Total bil; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Total bil; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Calcium; any Grade increase; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Calcium; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Calcium; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Creatinine; any Grade increase; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Creatinine; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Creatinine; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
GGT; any Grade increase; n=1,3,2,5,4,14
|
1 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
8 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
GGT; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
GGT; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Glucose; any Grade increase; n=1,3,2,5,4,14
|
1 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
4 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Glucose; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Glucose; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Potassium; any Grade increase; n=1,3,2,5,4,14
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Potassium; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Potassium; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Magnesium; any Grade increase; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
4 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Magnesium; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Magnesium; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Sodium; any Grade increase; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
4 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Sodium; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Sodium; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Phosphorus; any Grade increase; n=1,3,2,5,4,14
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Phosphorus; increase to Grade 3; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Phosphorus; increase to Grade 4; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Uric acid; any Grade increase; n=0,0,0,0,0,1
|
—
|
—
|
—
|
—
|
—
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Uric acid; increase to Grade 3; n=0,0,0,0,0,1
|
—
|
—
|
—
|
—
|
—
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2
Uric acid; increase to Grade 4; n=0,0,0,0,0,1
|
—
|
—
|
—
|
—
|
—
|
1 Participants
|
PRIMARY outcome
Timeframe: Baseline and median of 6.143 weeks of drug exposurePopulation: All Treated Population. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles).
Blood samples were collected for the analysis of following clinical chemistry parameters: direct bilirubin (D.Bil.), cancer antigen (CA)-125, CA-15.3, CA19-9, chloride, carbon dioxide (CO2)/bicarbonate (HCO3), luteinizing hormone (LH), total protein and urea or blood urea nitrogen (BUN). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Number of participants with change from Baseline in clinical chemistry data at worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
CA-125; Decrease to Low; n=1,3,0,5,4, 0
|
0 Participants
|
0 Participants
|
—
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
CA-125; increase to high; n=1,3,0,5,4, 0
|
0 Participants
|
0 Participants
|
—
|
0 Participants
|
0 Participants
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
CA 15.3; Decrease to Low; n=0, 0, 0, 0, 4, 0
|
—
|
—
|
—
|
—
|
0 Participants
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
CA 15.3; increase to high; n=0, 0, 0, 0, 4, 0
|
—
|
—
|
—
|
—
|
0 Participants
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
CA 19-9.; Decrease to Low; n=1,0,0,0,2,0
|
0 Participants
|
—
|
—
|
—
|
0 Participants
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
CA 19-9; increase to high; n=1,0,0,0,2,0
|
0 Participants
|
—
|
—
|
—
|
0 Participants
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
Chloride; Decrease to Low; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
Chloride; increase to high; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
CO2/HCO3.; Decrease to Low; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
CO2/HCO3; increase to high; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
7 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
LH; Decrease to Low; n=1,0,2,3,2,7
|
0 Participants
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
LH; increase to high; n=1,0,2,3,2,7
|
0 Participants
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
Total Protein; Decrease to Low; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
Total Protein; increase to high; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
Urea/BUN; Decrease to Low; n=1,3,2,5,4,14
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
Urea/BUN; increase to high; n=1,3,2,5,4,14
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
D.Bil.; increase to high; n=1,3,2,5,3,14
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2
D.Bil.; Decrease to Low; n=1,3,2,5,3,14
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline and median of 6.143 weeks of drug exposurePopulation: All Treated Population
Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, total neutrophils, platelet count, and white blood cell (WBC). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. Number of participants with any grade increase, increase to Grade 3 and increase to Grade 4 in hematology data at worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
WBC; increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Hemoglobin; any Grade increase
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
7 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Hemoglobin; increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Hemoglobin; increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Lymphocytes; any grade increase
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
5 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Lymphocytes; increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Lymphocytes; increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Total neutrophils; any Grade increase
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Total neutrophils; increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Total neutrophils; increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Platelet; any Grade increase
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Platelet; increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
Platelet; increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
WBC; any Grade increase
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2
WBC; increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline and median of 6.143 weeks of drug exposurePopulation: All Treated Population
Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, hematocrit, mean corpuscle hemoglobin concentration (MCHC), mean corpuscle hemoglobin (MCH), mean corpuscle volume (MCV), monocytes, red blood cell count (RBC) and reticulocytes. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as value at visit minus Baseline value. Number of participants with change from Baseline in hematology data at worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Basophils: decrease to low
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Basophils: increase to high
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Eosinophils: decrease to low
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Eosinophils: increase to high
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Hematocrit: decrease to low
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Hematocrit: increase to high
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
MCHC: decrease to low
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
MCHC: increase to high
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
MCH: decrease to low
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
MCH: increase to high
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
MCV: decrease to low
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
MCV: increase to high
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Monocytes: decrease to low
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Monocytes: increase to high
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
RBC: decrease to low
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
0 Participants
|
7 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
RBC: increase to high
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Reticulocytes: decrease to low
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2
Reticulocytes: increase to high
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Baseline and median of 6.143 weeks of drug exposurePopulation: All Treated Population. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles).
Urine samples were collected for the analysis of urine potential of hydrogen (pH) and urine specific gravity. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. The data for worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Urinalysis Data With Respect to Normal Range-Parts 1 and 2
Urine pH; decrease to low; n=1, 3, 1, 5, 4, 7
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Urinalysis Data With Respect to Normal Range-Parts 1 and 2
Urine pH; increase to high; n=1, 3, 1, 5, 4, 7
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Urinalysis Data With Respect to Normal Range-Parts 1 and 2
Specific gravity; decrease to low; n=1,3,1,4,4,8
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Urinalysis Data With Respect to Normal Range-Parts 1 and 2
Specific gravity; increase to high; n=1,3,1,4,4,8
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline and median of 6.143 weeks of drug exposurePopulation: All Treated Population
Vital sign measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). Vital signs were graded according to NCI-CTCAE version 4.0. The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in HR (decrease to \<60 beats per minute and increase to \>100 beats per minute); increase in SBP from Baseline (\>=120 to \<140 millimeters of mercury \[mmHg\] Grade 1; \>=140 to \<160 mmHg \[Grade 2\]; \>=160 \[Grade 3\]); increase in DBP from Baseline (\>=80 to \<90 \[Grade 1\]; \>=90 to \<100 \[Grade 2\]; \>=100 mmHg \[Grade 3\]) and change in temperature from Baseline (increase to \>=38 or decrease to \<=35 degree Centigrade). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. The data for worst-case post Baseline is presented.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
HR; increase to >100 beats per minute
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
5 Participants
|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
HR; decrease to <60 beats per minute
|
1 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
Temp; decrease to <=35 degree Celsius
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
Temp; increase to >=38 degree Celsius
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
SBP; increase to Grade 1 (120-139 mmHg)
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
SBP; increase to Grade 2 (140-159 mmHg)
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
SBP; increase to Grade 3 (>=160 mmHg)
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
DBP; increase to Grade 1 (80-89 mmHg)
|
0 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
1 Participants
|
7 Participants
|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
DBP; increase to Grade 2 (90-99 mmHg)
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2
DBP; increase to Grade 3 (>=100 mmHg)
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Median of 6.143 weeks of drug exposurePopulation: All Treated Population
A 12-lead ECG was measured using an automated ECG machine after at least 5 minutes of rest for the participant in a semi-recumbent or supine position. Number of participants with abnormal ECG findings at any time post-Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Parts 1 and 2
Abnormal-not clinically significant
|
1 Participants
|
3 Participants
|
1 Participants
|
4 Participants
|
3 Participants
|
4 Participants
|
|
Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Parts 1 and 2
Abnormal-clinically significant
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dosePopulation: PK Parameter Population
The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data is defined as Cmax. Blood samples were collected at indicated time points. The analysis was performed on pharmacokinetic (PK) parameter population which comprised of all participants from the PK concentration population (participants who received at least one dose of GSK2849330 and for whom at least one post-dose PK sample was obtained and analyzed) for whom valid and valuable PK parameters were derived.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=5 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax) of GSK2849330-Part 1
|
29790.0 Nanograms per milliliter
Geometric Coefficient of Variation NA
The geometric coefficient of variation could not be calculated as a single participant was analyzed at the specified time point.
|
62495.2 Nanograms per milliliter
Geometric Coefficient of Variation 34.8
|
83845.0 Nanograms per milliliter
Geometric Coefficient of Variation 24.1
|
233997.8 Nanograms per milliliter
Geometric Coefficient of Variation 2.7
|
639127.3 Nanograms per milliliter
Geometric Coefficient of Variation 45.4
|
778470.6 Nanograms per milliliter
Geometric Coefficient of Variation 14.5
|
SECONDARY outcome
Timeframe: Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dosePopulation: PK Parameter Population. PK parameters for Part 2 were not analyzed due to sparse sampling.
PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dosePopulation: PK Parameter Population
The time at which Cmax is observed was determined directly from the raw concentration-time data is defined as Tmax. Blood samples were collected at indicated time points for evaluation of pharmacokinetic parameters.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=5 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Time of Occurrence of Cmax (Tmax) for GSK2849330-Part 1
|
2.070 Hours
Interval 2.07 to 2.07
|
2.130 Hours
Interval 2.0 to 6.17
|
88.035 Hours
Interval 6.37 to 169.7
|
2.280 Hours
Interval 2.13 to 6.0
|
3.280 Hours
Interval 2.3 to 6.23
|
2.100 Hours
Interval 1.83 to 2.33
|
SECONDARY outcome
Timeframe: Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dosePopulation: PK Parameter Population. PK parameters for Part 2 were not analyzed due to sparse sampling.
PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dosePopulation: PK Parameter Population. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles).
The AUC to a fixed nominal time AUC(0-168) and AUC(0-336) were calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Blood samples were collected at indicated time points for determination of PK parameters.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=5 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Area Under the Concentration Time Curve (AUC) to a Fixed Nominal Time (AUC[0 to 168]) and AUC(0 to 336) for GSK2849330-Part 1
AUC(0 to 168); n=1, 3, 2, 3, 3, 5
|
1962762.0 Hours*nanogram per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated as a single participant was analyzed at the specified time point.
|
5787797.8 Hours*nanogram per milliliter
Geometric Coefficient of Variation 27.2
|
618552.6 Hours*nanogram per milliliter
Geometric Coefficient of Variation 20559.2
|
18185733.6 Hours*nanogram per milliliter
Geometric Coefficient of Variation 28.8
|
54346531.5 Hours*nanogram per milliliter
Geometric Coefficient of Variation 30.2
|
54388333.7 Hours*nanogram per milliliter
Geometric Coefficient of Variation 22.6
|
|
Area Under the Concentration Time Curve (AUC) to a Fixed Nominal Time (AUC[0 to 168]) and AUC(0 to 336) for GSK2849330-Part 1
AUC(0 to 336); 0, 3, 0, 3, 3, 0
|
—
|
7855808.8 Hours*nanogram per milliliter
Geometric Coefficient of Variation 28.7
|
—
|
23409694.6 Hours*nanogram per milliliter
Geometric Coefficient of Variation 39.4
|
72404738.6 Hours*nanogram per milliliter
Geometric Coefficient of Variation 34.2
|
—
|
SECONDARY outcome
Timeframe: Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dosePopulation: PK Parameter Population. PK parameters for Part 2 were not analyzed due to sparse sampling.
PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 1 (pre-dose, 1 hour, 6 hours), Day 2, Day 8, Day 15, Day 29 and follow-up (28 days post last dose)Population: PD Population. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles).
Pre-treatment and on-treatment biopsy tissues (tumor and normal skin) were analyzed for markers of HER3 pathway such as HER3 that may indicate a pharmacodynamic (PD) response to GSK2849330. Serum HER3 (soluble HER3) analyses was performed. The analysis was performed on PD population which comprised of all participants who received at least one dose of GSK2849330 and for whom at least one evaluable paired pre-treatment PD sample and on-treatment PD sample were obtained and analyzed. Mean and standard deviation for serum HER3 is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=12 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Serum HER3 From Tumor Tissue-Parts 1 and 2
Day 1; pre-dose; n=1, 3, 1, 5, 4, 12
|
13.65 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.11 Nanomoles
Standard Deviation 2.603
|
16.66 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.42 Nanomoles
Standard Deviation 4.004
|
13.67 Nanomoles
Standard Deviation 4.681
|
11.08 Nanomoles
Standard Deviation 5.322
|
|
Serum HER3 From Tumor Tissue-Parts 1 and 2
Follow-up; n=1, 2, 1, 3, 2, 5
|
6.19 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.22 Nanomoles
Standard Deviation 3.090
|
14.86 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.41 Nanomoles
Standard Deviation 1.406
|
3.73 Nanomoles
Standard Deviation 0.424
|
4.39 Nanomoles
Standard Deviation 2.975
|
|
Serum HER3 From Tumor Tissue-Parts 1 and 2
Day 1; 1 hour; n=1, 3, 1, 5, 4, 11
|
11.12 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.14 Nanomoles
Standard Deviation 2.966
|
7.53 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.76 Nanomoles
Standard Deviation 2.228
|
9.55 Nanomoles
Standard Deviation 4.437
|
5.59 Nanomoles
Standard Deviation 2.709
|
|
Serum HER3 From Tumor Tissue-Parts 1 and 2
Day 1; 6 hours; n=1, 3, 1, 5, 4, 10
|
9.88 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.71 Nanomoles
Standard Deviation 2.679
|
12.99 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.69 Nanomoles
Standard Deviation 4.058
|
9.39 Nanomoles
Standard Deviation 4.586
|
5.35 Nanomoles
Standard Deviation 2.031
|
|
Serum HER3 From Tumor Tissue-Parts 1 and 2
Day 2; n=0, 0, 1, 1, 1, 2
|
—
|
—
|
8.12 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.15 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.59 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
3.50 Nanomoles
Standard Deviation 2.001
|
|
Serum HER3 From Tumor Tissue-Parts 1 and 2
Day 8; n=1, 3, 1, 5, 4, 11
|
10.14 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.59 Nanomoles
Standard Deviation 4.353
|
10.87 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.85 Nanomoles
Standard Deviation 3.771
|
6.32 Nanomoles
Standard Deviation 2.702
|
6.05 Nanomoles
Standard Deviation 2.382
|
|
Serum HER3 From Tumor Tissue-Parts 1 and 2
Day 15; n=0, 2, 1, 3, 4, 10
|
—
|
10.62 Nanomoles
Standard Deviation 1.110
|
7.37 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.38 Nanomoles
Standard Deviation 3.535
|
9.84 Nanomoles
Standard Deviation 3.127
|
4.66 Nanomoles
Standard Deviation 1.402
|
|
Serum HER3 From Tumor Tissue-Parts 1 and 2
Day 29; n=1, 3, 1, 4, 4, 8
|
10.99 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.18 Nanomoles
Standard Deviation 3.695
|
7.69 Nanomoles
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.60 Nanomoles
Standard Deviation 3.220
|
6.91 Nanomoles
Standard Deviation 4.621
|
4.13 Nanomoles
Standard Deviation 1.815
|
SECONDARY outcome
Timeframe: Median of 6.143 weeks of drug exposurePopulation: All Treated Population
ORR was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). ORR was calculated as the number of participants with best overall response of complete response (CR) and partial response (PR). CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter (mm) in the short axis and PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters (e.g., percent change from Baseline). An estimate to the true response rate for the number of participants analyzed is given. The 95% confidence interval was the exact confidence interval based on binomial proportion for ORR. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Overall Response Rate (ORR)-Parts 1 and 2
|
0 Participants
Interval 0.0 to 97.5
|
0 Participants
Interval 0.0 to 70.8
|
0 Participants
Interval 0.0 to 84.2
|
0 Participants
Interval 0.0 to 52.2
|
0 Participants
Interval 0.0 to 60.2
|
1 Participants
Interval 0.2 to 33.9
|
SECONDARY outcome
Timeframe: Median of 6.143 weeks of drug exposurePopulation: All Treated Population. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles)
Serum samples were collected for the determination of anti-GSK2849330 antibodies using a validated immunoelectrochemiluminescent (ECL) assay. The assay involved screening, confirmation and titration steps (tiered-testing approach). If serum samples contained anti-GSK2849330 antibodies, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants who tested positive for anti-GSK2849330 antibody in confirmatory testing on Day 1 and at any time post-Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Number of Participants With Antibodies to GSK2849330 in Serum
Day1; n=1, 3, 2, 5, 4, 13
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Antibodies to GSK2849330 in Serum
Any time post-Baseline; n=1, 3, 1, 5, 4, 7
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Median of 6.143 weeks of drug exposurePopulation: PD Population. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles)
Blood samples were collected on Day (D) 1 at pre-dose (pre) and at 1 hour (h) and 6 h post infusion for the analysis of markers to evaluate biological activity of GSK2849330. A pre-dose blood sample was collected on D8, D15 and D29 with additional blood sample collected at progression of disease. CDX241 represent CD45+CD3-CD56+CD16+CD69+CD107+, CDX243=CD45+CD3-CD56+CD16+CD69+CD107-; CDX244=CD45+CD3-CD56+CD16+CD69-CD107+ and CDX245=CD45+CD3-CD56+CD16+CD69-CD107-. For participants in GSK2849330 3 mg/kg weekly arm, two samples (S1 and S2) were collected for D15 analysis. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
Outcome measures
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 Participants
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=1 Participants
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 Participants
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 Participants
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=12 Participants
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; D29; n=1, 3, 1, 4, 4, 8
|
99.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.93 Percentage of CD marker cells
Standard Deviation 0.058
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.78 Percentage of CD marker cells
Standard Deviation 0.222
|
99.75 Percentage of CD marker cells
Standard Deviation 0.436
|
100.80 Percentage of CD marker cells
Standard Deviation 3.746
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; D1; 6 h; n=1, 3, 1, 5, 4, 11
|
81.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
72.43 Percentage of CD marker cells
Standard Deviation 12.784
|
62.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
86.88 Percentage of CD marker cells
Standard Deviation 2.580
|
77.83 Percentage of CD marker cells
Standard Deviation 5.065
|
72.16 Percentage of CD marker cells
Standard Deviation 10.282
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; D1; pre;n=1, 3, 1, 5, 4, 9
|
9.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.67 Percentage of CD marker cells
Standard Deviation 6.929
|
21.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
35.14 Percentage of CD marker cells
Standard Deviation 22.721
|
24.95 Percentage of CD marker cells
Standard Deviation 13.644
|
25.39 Percentage of CD marker cells
Standard Deviation 11.076
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; D29; n=1, 3, 1, 4, 4, 8
|
11.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.83 Percentage of CD marker cells
Standard Deviation 9.530
|
37.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.75 Percentage of CD marker cells
Standard Deviation 2.654
|
10.73 Percentage of CD marker cells
Standard Deviation 9.999
|
11.93 Percentage of CD marker cells
Standard Deviation 7.323
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; D29; n=1, 3, 1, 4, 4, 8
|
13.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.90 Percentage of CD marker cells
Standard Deviation 8.502
|
42.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.18 Percentage of CD marker cells
Standard Deviation 2.428
|
13.73 Percentage of CD marker cells
Standard Deviation 9.582
|
12.48 Percentage of CD marker cells
Standard Deviation 9.517
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+; D29; n=1,3,1,4,4,8
|
15.85 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.77 Percentage of CD marker cells
Standard Deviation 3.841
|
48.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.09 Percentage of CD marker cells
Standard Deviation 1.735
|
22.89 Percentage of CD marker cells
Standard Deviation 7.527
|
17.13 Percentage of CD marker cells
Standard Deviation 5.406
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+; D1;1 h;n=1,3,1,5,4,9
|
4.97 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.56 Percentage of CD marker cells
Standard Deviation 7.455
|
6.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.90 Percentage of CD marker cells
Standard Deviation 11.974
|
17.72 Percentage of CD marker cells
Standard Deviation 8.423
|
13.60 Percentage of CD marker cells
Standard Deviation 14.641
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
25.26 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
32.24 Percentage of CD marker cells
Standard Deviation 9.970
|
—
|
30.57 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+; FU; n=1,2,0,3,1,4
|
13.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.58 Percentage of CD marker cells
Standard Deviation 14.078
|
—
|
29.76 Percentage of CD marker cells
Standard Deviation 28.400
|
11.68 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
25.61 Percentage of CD marker cells
Standard Deviation 14.702
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243; D8; n=1,3,0,5,4,8
|
44.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
68.91 Percentage of CD marker cells
Standard Deviation 8.623
|
—
|
62.04 Percentage of CD marker cells
Standard Deviation 7.093
|
65.87 Percentage of CD marker cells
Standard Deviation 2.821
|
44.43 Percentage of CD marker cells
Standard Deviation 22.911
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+;D1pre; n=1,3,1,5,4,9
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.19 Percentage of CD marker cells
Standard Deviation 0.163
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.84 Percentage of CD marker cells
Standard Deviation 1.119
|
0.62 Percentage of CD marker cells
Standard Deviation 0.761
|
0.77 Percentage of CD marker cells
Standard Deviation 1.157
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+; D15;S1; n=1,3,1,5,4,9
|
66.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
70.12 Percentage of CD marker cells
Standard Deviation 3.641
|
67.74 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
72.11 Percentage of CD marker cells
Standard Deviation 5.807
|
65.46 Percentage of CD marker cells
Standard Deviation 2.301
|
58.44 Percentage of CD marker cells
Standard Deviation 20.646
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-;D1pre; n=1,3,1,5,4,9
|
48.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
47.30 Percentage of CD marker cells
Standard Deviation 5.590
|
43.27 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
46.85 Percentage of CD marker cells
Standard Deviation 9.558
|
50.59 Percentage of CD marker cells
Standard Deviation 11.155
|
51.99 Percentage of CD marker cells
Standard Deviation 13.129
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; D15; S1; n=1,3,1,5,4,9
|
18.22 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.46 Percentage of CD marker cells
Standard Deviation 3.242
|
2.88 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.00 Percentage of CD marker cells
Standard Deviation 6.887
|
19.16 Percentage of CD marker cells
Standard Deviation 5.695
|
20.48 Percentage of CD marker cells
Standard Deviation 19.116
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
5.58 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; D29; n=1,3,1,4,4,8
|
20.48 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.10 Percentage of CD marker cells
Standard Deviation 2.566
|
12.58 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.57 Percentage of CD marker cells
Standard Deviation 7.550
|
17.45 Percentage of CD marker cells
Standard Deviation 4.991
|
23.93 Percentage of CD marker cells
Standard Deviation 16.995
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; FU; n=1,2,0,3,1,4
|
22.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.91 Percentage of CD marker cells
Standard Deviation 1.075
|
—
|
18.72 Percentage of CD marker cells
Standard Deviation 12.153
|
23.19 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.88 Percentage of CD marker cells
Standard Deviation 18.996
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; USC; n=0,0,1,0,0,0
|
—
|
—
|
33.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+;D1pre; n=1,3,1,5,4,9
|
62.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
77.83 Percentage of CD marker cells
Standard Deviation 5.748
|
84.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
76.05 Percentage of CD marker cells
Standard Deviation 13.328
|
80.50 Percentage of CD marker cells
Standard Deviation 5.553
|
72.52 Percentage of CD marker cells
Standard Deviation 20.777
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+;D1;1 h;n=1,3,1,5,4,9
|
71.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
77.91 Percentage of CD marker cells
Standard Deviation 8.757
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
74.68 Percentage of CD marker cells
Standard Deviation 12.530
|
76.76 Percentage of CD marker cells
Standard Deviation 7.819
|
69.96 Percentage of CD marker cells
Standard Deviation 23.711
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+;D1;6 h;n=1,3,1,5,4,11
|
77.14 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
76.55 Percentage of CD marker cells
Standard Deviation 11.000
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
75.64 Percentage of CD marker cells
Standard Deviation 10.831
|
77.96 Percentage of CD marker cells
Standard Deviation 9.405
|
73.92 Percentage of CD marker cells
Standard Deviation 20.707
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+; D2; n=0,0,1,2,0,1
|
—
|
—
|
90.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
79.51 Percentage of CD marker cells
Standard Deviation 11.823
|
—
|
81.34 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+; D8; n=1,3,0,5,4,8
|
70.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
79.41 Percentage of CD marker cells
Standard Deviation 6.359
|
—
|
77.26 Percentage of CD marker cells
Standard Deviation 8.083
|
77.76 Percentage of CD marker cells
Standard Deviation 3.671
|
71.42 Percentage of CD marker cells
Standard Deviation 17.583
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+; D15;S1; n=1,3,1,5,4,9
|
76.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
81.26 Percentage of CD marker cells
Standard Deviation 7.195
|
100 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
76.72 Percentage of CD marker cells
Standard Deviation 9.716
|
75.78 Percentage of CD marker cells
Standard Deviation 3.311
|
72.29 Percentage of CD marker cells
Standard Deviation 22.078
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+;D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
90.91 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+; D29; n=1,3,1,4,4,8
|
76.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
84.46 Percentage of CD marker cells
Standard Deviation 9.848
|
92.11 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
75.11 Percentage of CD marker cells
Standard Deviation 5.695
|
79.47 Percentage of CD marker cells
Standard Deviation 4.516
|
73.25 Percentage of CD marker cells
Standard Deviation 19.837
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+; FU;n=1,2,0,3,1,4
|
76.95 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
83.76 Percentage of CD marker cells
Standard Deviation 2.977
|
—
|
76.93 Percentage of CD marker cells
Standard Deviation 2.841
|
78.84 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
78.73 Percentage of CD marker cells
Standard Deviation 13.208
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+; USC;n=0,0,1,0,0,0
|
—
|
—
|
73.08 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+;D1pre; n=1,3,1,5,4,9
|
8.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.44 Percentage of CD marker cells
Standard Deviation 3.025
|
30.77 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.69 Percentage of CD marker cells
Standard Deviation 14.219
|
25.59 Percentage of CD marker cells
Standard Deviation 10.582
|
21.94 Percentage of CD marker cells
Standard Deviation 11.569
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+;D1;1 h;n=1,3,1,5,4,9
|
16.16 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
25.59 Percentage of CD marker cells
Standard Deviation 8.435
|
16.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
25.84 Percentage of CD marker cells
Standard Deviation 13.782
|
20.17 Percentage of CD marker cells
Standard Deviation 7.408
|
19.38 Percentage of CD marker cells
Standard Deviation 9.838
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+;D1;6 h;n=1,3,1,5,4,11
|
17.14 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.55 Percentage of CD marker cells
Standard Deviation 9.084
|
77.27 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
25.54 Percentage of CD marker cells
Standard Deviation 14.785
|
18.38 Percentage of CD marker cells
Standard Deviation 7.558
|
27.83 Percentage of CD marker cells
Standard Deviation 16.580
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
50.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.40 Percentage of CD marker cells
Standard Deviation 2.892
|
—
|
21.27 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+; D8; n=1,3,0,5,4,8
|
34.51 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
25.08 Percentage of CD marker cells
Standard Deviation 12.140
|
—
|
22.70 Percentage of CD marker cells
Standard Deviation 6.042
|
23.85 Percentage of CD marker cells
Standard Deviation 15.031
|
25.37 Percentage of CD marker cells
Standard Deviation 9.055
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+; D15; S1;n=1,3,1,5,4,9
|
24.44 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.39 Percentage of CD marker cells
Standard Deviation 9.804
|
66.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.15 Percentage of CD marker cells
Standard Deviation 15.543
|
22.75 Percentage of CD marker cells
Standard Deviation 9.361
|
24.77 Percentage of CD marker cells
Standard Deviation 13.389
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+;D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
91.36 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+; D29; n=1,3,1,4,4,8
|
19.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.61 Percentage of CD marker cells
Standard Deviation 12.809
|
94.74 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.97 Percentage of CD marker cells
Standard Deviation 16.720
|
26.64 Percentage of CD marker cells
Standard Deviation 16.501
|
25.47 Percentage of CD marker cells
Standard Deviation 7.825
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+; FU;n=1,2,0,3,1,4
|
19.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.79 Percentage of CD marker cells
Standard Deviation 8.132
|
—
|
32.87 Percentage of CD marker cells
Standard Deviation 23.340
|
16.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
26.92 Percentage of CD marker cells
Standard Deviation 16.312
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
20.51 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+;D1;pre; n=1,3,1,5,4,9
|
8.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.26 Percentage of CD marker cells
Standard Deviation 2.974
|
30.77 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.85 Percentage of CD marker cells
Standard Deviation 14.628
|
24.97 Percentage of CD marker cells
Standard Deviation 10.148
|
21.16 Percentage of CD marker cells
Standard Deviation 11.995
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+;D1;1 h;n=1,3,1,5,4,9
|
15.15 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
25.29 Percentage of CD marker cells
Standard Deviation 8.566
|
16.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.96 Percentage of CD marker cells
Standard Deviation 14.211
|
19.58 Percentage of CD marker cells
Standard Deviation 6.559
|
18.93 Percentage of CD marker cells
Standard Deviation 9.947
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
|
17.14 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
26.84 Percentage of CD marker cells
Standard Deviation 8.938
|
77.27 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.77 Percentage of CD marker cells
Standard Deviation 15.022
|
17.89 Percentage of CD marker cells
Standard Deviation 7.034
|
26.49 Percentage of CD marker cells
Standard Deviation 16.563
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
50.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.24 Percentage of CD marker cells
Standard Deviation 3.111
|
—
|
20.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+; D8; n=1,3,0,5,4,8
|
32.08 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.24 Percentage of CD marker cells
Standard Deviation 11.427
|
—
|
22.33 Percentage of CD marker cells
Standard Deviation 5.946
|
23.10 Percentage of CD marker cells
Standard Deviation 14.534
|
24.68 Percentage of CD marker cells
Standard Deviation 9.353
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+; D15;S1; n=1,3,1,5,4,9
|
24.12 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.22 Percentage of CD marker cells
Standard Deviation 9.646
|
66.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.78 Percentage of CD marker cells
Standard Deviation 15.294
|
22.25 Percentage of CD marker cells
Standard Deviation 9.194
|
23.91 Percentage of CD marker cells
Standard Deviation 13.531
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+;D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
85.45 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+; D29; n=1,3,1,4,4,8
|
18.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.31 Percentage of CD marker cells
Standard Deviation 12.597
|
86.84 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.41 Percentage of CD marker cells
Standard Deviation 16.520
|
25.87 Percentage of CD marker cells
Standard Deviation 15.887
|
23.72 Percentage of CD marker cells
Standard Deviation 7.717
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+; FU;n=1,2,0,3,1,4
|
19.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.48 Percentage of CD marker cells
Standard Deviation 8.217
|
—
|
31.89 Percentage of CD marker cells
Standard Deviation 22.622
|
15.87 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
26.51 Percentage of CD marker cells
Standard Deviation 16.034
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
16.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-;D1; pre; n=1,3,1,5,4,9
|
54.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
54.57 Percentage of CD marker cells
Standard Deviation 2.810
|
53.85 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.20 Percentage of CD marker cells
Standard Deviation 11.519
|
55.53 Percentage of CD marker cells
Standard Deviation 15.219
|
51.35 Percentage of CD marker cells
Standard Deviation 15.196
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9
|
56.06 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.62 Percentage of CD marker cells
Standard Deviation 3.308
|
83.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
49.72 Percentage of CD marker cells
Standard Deviation 10.923
|
57.19 Percentage of CD marker cells
Standard Deviation 10.200
|
51.04 Percentage of CD marker cells
Standard Deviation 17.281
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
|
60.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
49.71 Percentage of CD marker cells
Standard Deviation 2.501
|
22.73 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
50.88 Percentage of CD marker cells
Standard Deviation 11.326
|
60.07 Percentage of CD marker cells
Standard Deviation 13.763
|
47.43 Percentage of CD marker cells
Standard Deviation 15.287
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
40.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
67.28 Percentage of CD marker cells
Standard Deviation 8.719
|
—
|
60.45 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-; D8; n=1,3,0,5,4,8
|
38.27 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
55.17 Percentage of CD marker cells
Standard Deviation 6.740
|
—
|
54.92 Percentage of CD marker cells
Standard Deviation 10.367
|
54.67 Percentage of CD marker cells
Standard Deviation 12.323
|
46.74 Percentage of CD marker cells
Standard Deviation 9.237
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-; D15;S1; n=1,3,1,5,4,9
|
52.41 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
65.04 Percentage of CD marker cells
Standard Deviation 6.660
|
33.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
56.94 Percentage of CD marker cells
Standard Deviation 9.081
|
53.53 Percentage of CD marker cells
Standard Deviation 10.408
|
48.38 Percentage of CD marker cells
Standard Deviation 17.947
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-;D15;S2;n=0,0,1,0,0,0
|
—
|
—
|
5.45 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-; D29; n=1,3,1,4,4,8
|
57.87 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
60.14 Percentage of CD marker cells
Standard Deviation 4.928
|
5.26 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
53.70 Percentage of CD marker cells
Standard Deviation 12.139
|
53.61 Percentage of CD marker cells
Standard Deviation 15.433
|
49.53 Percentage of CD marker cells
Standard Deviation 16.556
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-; FU;n=1,2,0,3,1,4
|
57.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
56.28 Percentage of CD marker cells
Standard Deviation 5.240
|
—
|
45.05 Percentage of CD marker cells
Standard Deviation 22.028
|
62.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.22 Percentage of CD marker cells
Standard Deviation 5.130
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69+CD107-; USC;n=0,0,1,0,0,0
|
—
|
—
|
56.41 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9
|
1.01 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.30 Percentage of CD marker cells
Standard Deviation 0.295
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.87 Percentage of CD marker cells
Standard Deviation 1.493
|
0.59 Percentage of CD marker cells
Standard Deviation 0.889
|
0.45 Percentage of CD marker cells
Standard Deviation 0.501
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.72 Percentage of CD marker cells
Standard Deviation 0.806
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.77 Percentage of CD marker cells
Standard Deviation 1.369
|
0.49 Percentage of CD marker cells
Standard Deviation 0.666
|
1.35 Percentage of CD marker cells
Standard Deviation 2.225
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.16 Percentage of CD marker cells
Standard Deviation 0.219
|
—
|
0.37 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+; D8; n=1,3,0,5,4,8
|
2.43 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.84 Percentage of CD marker cells
Standard Deviation 0.716
|
—
|
0.37 Percentage of CD marker cells
Standard Deviation 0.613
|
0.75 Percentage of CD marker cells
Standard Deviation 0.573
|
0.69 Percentage of CD marker cells
Standard Deviation 0.656
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+; D15;S1;n=1,3,1,5,4,9
|
0.32 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.17 Percentage of CD marker cells
Standard Deviation 0.300
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.37 Percentage of CD marker cells
Standard Deviation 0.288
|
0.51 Percentage of CD marker cells
Standard Deviation 0.307
|
0.87 Percentage of CD marker cells
Standard Deviation 1.194
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9
|
44.32 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
45.95 Percentage of CD marker cells
Standard Deviation 6.784
|
62.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
44.76 Percentage of CD marker cells
Standard Deviation 7.470
|
52.17 Percentage of CD marker cells
Standard Deviation 7.570
|
51.12 Percentage of CD marker cells
Standard Deviation 15.653
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
|
56.47 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
43.85 Percentage of CD marker cells
Standard Deviation 7.548
|
45.95 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
47.05 Percentage of CD marker cells
Standard Deviation 7.908
|
52.61 Percentage of CD marker cells
Standard Deviation 7.942
|
50.61 Percentage of CD marker cells
Standard Deviation 11.996
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
46.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
60.93 Percentage of CD marker cells
Standard Deviation 12.282
|
—
|
57.57 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-; D8; n=1,3,0,5,4,8
|
29.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
47.53 Percentage of CD marker cells
Standard Deviation 4.483
|
—
|
48.36 Percentage of CD marker cells
Standard Deviation 11.067
|
50.52 Percentage of CD marker cells
Standard Deviation 8.995
|
47.22 Percentage of CD marker cells
Standard Deviation 12.334
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-; D15; S1;n=1,3,1,5,4,9
|
46.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
58.77 Percentage of CD marker cells
Standard Deviation 6.439
|
3.23 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
51.49 Percentage of CD marker cells
Standard Deviation 9.965
|
47.99 Percentage of CD marker cells
Standard Deviation 7.314
|
44.65 Percentage of CD marker cells
Standard Deviation 18.062
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-; D15; S2;n=0,0,1,0,0,0
|
—
|
—
|
2.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-; D29; n=1,3,1,4,4,8
|
31.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
53.96 Percentage of CD marker cells
Standard Deviation 1.639
|
7.69 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
50.28 Percentage of CD marker cells
Standard Deviation 9.182
|
49.25 Percentage of CD marker cells
Standard Deviation 12.319
|
46.17 Percentage of CD marker cells
Standard Deviation 14.907
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-; FU;n=1,2,0,3,1,4
|
47.63 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.34 Percentage of CD marker cells
Standard Deviation 3.274
|
—
|
41.31 Percentage of CD marker cells
Standard Deviation 23.301
|
50.44 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
47.72 Percentage of CD marker cells
Standard Deviation 13.474
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107-; USC;n=0,0,1,0,0,0
|
—
|
—
|
32.81 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+;D1pre; n=1,3,1,5,4,9
|
0.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.76 Percentage of CD marker cells
Standard Deviation 0.475
|
0.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.03 Percentage of CD marker cells
Standard Deviation 1.228
|
0.61 Percentage of CD marker cells
Standard Deviation 0.493
|
0.54 Percentage of CD marker cells
Standard Deviation 0.575
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9
|
0.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.03 Percentage of CD marker cells
Standard Deviation 0.683
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.24 Percentage of CD marker cells
Standard Deviation 1.342
|
0.76 Percentage of CD marker cells
Standard Deviation 0.919
|
0.59 Percentage of CD marker cells
Standard Deviation 0.605
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
|
0.19 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.30 Percentage of CD marker cells
Standard Deviation 1.040
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.01 Percentage of CD marker cells
Standard Deviation 1.572
|
0.91 Percentage of CD marker cells
Standard Deviation 0.629
|
1.09 Percentage of CD marker cells
Standard Deviation 1.070
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+; D8; n=1,3,0,5,4,8
|
4.05 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.32 Percentage of CD marker cells
Standard Deviation 1.711
|
—
|
0.97 Percentage of CD marker cells
Standard Deviation 1.172
|
0.96 Percentage of CD marker cells
Standard Deviation 1.007
|
0.95 Percentage of CD marker cells
Standard Deviation 1.058
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+;D15;S2;n=0,0,1,0,0,0
|
—
|
—
|
5.91 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+; D29; n=1,3,1,4,4,8
|
0.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.29 Percentage of CD marker cells
Standard Deviation 0.409
|
7.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.57 Percentage of CD marker cells
Standard Deviation 0.312
|
0.77 Percentage of CD marker cells
Standard Deviation 0.697
|
1.75 Percentage of CD marker cells
Standard Deviation 2.925
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.37 Percentage of CD marker cells
Standard Deviation 0.516
|
—
|
0.06 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+; FU;n=1,2,0,3,1,4
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.31 Percentage of CD marker cells
Standard Deviation 0.085
|
—
|
0.98 Percentage of CD marker cells
Standard Deviation 1.235
|
0.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.41 Percentage of CD marker cells
Standard Deviation 0.407
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+; D15;S1;n=1,3,1,5,4,9
|
1.23 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.24 Percentage of CD marker cells
Standard Deviation 0.163
|
29.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.48 Percentage of CD marker cells
Standard Deviation 0.609
|
1.05 Percentage of CD marker cells
Standard Deviation 0.920
|
0.73 Percentage of CD marker cells
Standard Deviation 0.435
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
3.85 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-;D1pre; n=1,3,1,5,4,9
|
37.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.98 Percentage of CD marker cells
Standard Deviation 5.814
|
15.38 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.11 Percentage of CD marker cells
Standard Deviation 12.486
|
18.88 Percentage of CD marker cells
Standard Deviation 5.007
|
26.71 Percentage of CD marker cells
Standard Deviation 19.740
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9
|
27.78 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.78 Percentage of CD marker cells
Standard Deviation 8.736
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.444 Percentage of CD marker cells
Standard Deviation 11.410
|
22.65 Percentage of CD marker cells
Standard Deviation 7.631
|
29.59 Percentage of CD marker cells
Standard Deviation 23.473
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
|
22.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.74 Percentage of CD marker cells
Standard Deviation 11.250
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.59 Percentage of CD marker cells
Standard Deviation 9.836
|
21.55 Percentage of CD marker cells
Standard Deviation 8.954
|
24.74 Percentage of CD marker cells
Standard Deviation 19.457
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
23.37 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+; D29; n=1,3,1,4,4,8
|
7.87 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.37 Percentage of CD marker cells
Standard Deviation 0.078
|
21.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.65 Percentage of CD marker cells
Standard Deviation 0.554
|
1.10 Percentage of CD marker cells
Standard Deviation 0.919
|
1.22 Percentage of CD marker cells
Standard Deviation 1.347
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+; FU;n=1,2,0,3,1,4
|
0.82 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.58 Percentage of CD marker cells
Standard Deviation 0.361
|
—
|
1.44 Percentage of CD marker cells
Standard Deviation 1.298
|
0.29 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.63 Percentage of CD marker cells
Standard Deviation 2.326
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
1.57 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-;D1pre; n=1,3,1,5,4,9
|
41.83 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
28.12 Percentage of CD marker cells
Standard Deviation 1.219
|
39.42 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
28.78 Percentage of CD marker cells
Standard Deviation 8.425
|
29.92 Percentage of CD marker cells
Standard Deviation 7.082
|
35.04 Percentage of CD marker cells
Standard Deviation 15.444
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
10.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.34 Percentage of CD marker cells
Standard Deviation 11.604
|
—
|
18.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9
|
44.65 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
32.42 Percentage of CD marker cells
Standard Deviation 1.397
|
33.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
30.37 Percentage of CD marker cells
Standard Deviation 7.516
|
29.97 Percentage of CD marker cells
Standard Deviation 10.290
|
36.79 Percentage of CD marker cells
Standard Deviation 18.243
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
|
29.64 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
33.94 Percentage of CD marker cells
Standard Deviation 1.914
|
18.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
31.34 Percentage of CD marker cells
Standard Deviation 7.255
|
29.65 Percentage of CD marker cells
Standard Deviation 10.132
|
34.81 Percentage of CD marker cells
Standard Deviation 15.738
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-; D8; n=1,3,0,5,4,8
|
27.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.75 Percentage of CD marker cells
Standard Deviation 7.018
|
—
|
22.38 Percentage of CD marker cells
Standard Deviation 7.709
|
21.49 Percentage of CD marker cells
Standard Deviation 4.140
|
27.89 Percentage of CD marker cells
Standard Deviation 17.180
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-; D15;S1; n=1,3,1,5,4,9
|
23.15 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.56 Percentage of CD marker cells
Standard Deviation 7.134
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.91 Percentage of CD marker cells
Standard Deviation 9.852
|
23.72 Percentage of CD marker cells
Standard Deviation 3.040
|
26.84 Percentage of CD marker cells
Standard Deviation 21.388
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
28.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.04 Percentage of CD marker cells
Standard Deviation 7.382
|
—
|
26.77 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-; D8; n=1,3,0,5,4,8
|
32.34 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
33.30 Percentage of CD marker cells
Standard Deviation 2.044
|
—
|
27.52 Percentage of CD marker cells
Standard Deviation 6.239
|
29.90 Percentage of CD marker cells
Standard Deviation 2.006
|
39.24 Percentage of CD marker cells
Standard Deviation 13.864
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-;D15;S2;n=0,0,1,0,0,0
|
—
|
—
|
3.18 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-; D29; n=1,3,1,4,4,8
|
22.93 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.25 Percentage of CD marker cells
Standard Deviation 9.918
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.33 Percentage of CD marker cells
Standard Deviation 5.914
|
19.76 Percentage of CD marker cells
Standard Deviation 4.920
|
25.00 Percentage of CD marker cells
Standard Deviation 18.022
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-; D15;S1; n=1,3,1,5,4,9
|
32.56 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
29.64 Percentage of CD marker cells
Standard Deviation 3.488
|
3.23 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.41 Percentage of CD marker cells
Standard Deviation 6.016
|
33.49 Percentage of CD marker cells
Standard Deviation 1.695
|
40.83 Percentage of CD marker cells
Standard Deviation 20.434
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-; FU;n=1,2,0,3,1,4
|
23.05 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.94 Percentage of CD marker cells
Standard Deviation 2.892
|
—
|
22.09 Percentage of CD marker cells
Standard Deviation 2.249
|
20.63 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.86 Percentage of CD marker cells
Standard Deviation 13.394
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+CD69-CD107-; USC;n=0,0,1,0,0,0
|
—
|
—
|
23.08 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+;D1pre; n=1,3,1,5,4,9
|
57.87 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
71.12 Percentage of CD marker cells
Standard Deviation 1.083
|
59.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
70.19 Percentage of CD marker cells
Standard Deviation 9.089
|
69.48 Percentage of CD marker cells
Standard Deviation 7.473
|
64.41 Percentage of CD marker cells
Standard Deviation 15.841
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+;D1;1 h;n=1,3,1,5,4,9
|
54.45 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
66.55 Percentage of CD marker cells
Standard Deviation 0.781
|
66.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
68.39 Percentage of CD marker cells
Standard Deviation 8.060
|
69.27 Percentage of CD marker cells
Standard Deviation 10.664
|
62.62 Percentage of CD marker cells
Standard Deviation 18.568
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+;D1;6 h;n=1,3,1,5,4,11
|
70.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
64.77 Percentage of CD marker cells
Standard Deviation 2.867
|
81.08 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
67.66 Percentage of CD marker cells
Standard Deviation 7.411
|
69.44 Percentage of CD marker cells
Standard Deviation 10.476
|
64.10 Percentage of CD marker cells
Standard Deviation 16.568
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
7.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-; D29; n=1,3,1,4,4,8
|
23.66 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.50 Percentage of CD marker cells
Standard Deviation 0.558
|
26.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
31.28 Percentage of CD marker cells
Standard Deviation 4.954
|
28.48 Percentage of CD marker cells
Standard Deviation 3.302
|
37.82 Percentage of CD marker cells
Standard Deviation 15.640
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-; FU;n=1,2,0,3,1,4
|
31.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.67 Percentage of CD marker cells
Standard Deviation 4.264
|
—
|
24.19 Percentage of CD marker cells
Standard Deviation 5.014
|
28.91 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.74 Percentage of CD marker cells
Standard Deviation 14.176
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69-CD107-; USC;n=0,0,1,0,0,0
|
—
|
—
|
53.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+;D1pre; n=1,3,1,5,4,9
|
49.72 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
64.40 Percentage of CD marker cells
Standard Deviation 2.410
|
61.84 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
64.96 Percentage of CD marker cells
Standard Deviation 9.980
|
63.78 Percentage of CD marker cells
Standard Deviation 9.470
|
57.37 Percentage of CD marker cells
Standard Deviation 19.984
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+;D1;1 h;n=1,3,1,5,4,9
|
50.16 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
60.66 Percentage of CD marker cells
Standard Deviation 4.707
|
67.16 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
63.58 Percentage of CD marker cells
Standard Deviation 8.122
|
62.71 Percentage of CD marker cells
Standard Deviation 13.023
|
55.80 Percentage of CD marker cells
Standard Deviation 21.386
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+;D1;6 h;n=1,3,1,5,4,11
|
63.54 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
61.49 Percentage of CD marker cells
Standard Deviation 3.426
|
80.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
62.24 Percentage of CD marker cells
Standard Deviation 7.910
|
63.26 Percentage of CD marker cells
Standard Deviation 12.922
|
60.07 Percentage of CD marker cells
Standard Deviation 19.171
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+; D2; n=0,0,1,2,0,1
|
—
|
—
|
68.61 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
69.01 Percentage of CD marker cells
Standard Deviation 3.783
|
—
|
62.93 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+; D8; n=1,3,0,5,4,8
|
58.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
59.29 Percentage of CD marker cells
Standard Deviation 5.515
|
—
|
64.97 Percentage of CD marker cells
Standard Deviation 2.165
|
65.73 Percentage of CD marker cells
Standard Deviation 6.597
|
51.29 Percentage of CD marker cells
Standard Deviation 13.826
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+; D15;S1; n=1,3,1,5,4,9
|
53.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
64.92 Percentage of CD marker cells
Standard Deviation 4.016
|
72.73 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
65.08 Percentage of CD marker cells
Standard Deviation 6.604
|
58.46 Percentage of CD marker cells
Standard Deviation 3.564
|
53.38 Percentage of CD marker cells
Standard Deviation 21.988
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
67.36 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+; D29; n=1,3,1,4,4,8
|
60.54 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
67.97 Percentage of CD marker cells
Standard Deviation 4.090
|
52.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
61.52 Percentage of CD marker cells
Standard Deviation 6.451
|
63.88 Percentage of CD marker cells
Standard Deviation 5.978
|
53.68 Percentage of CD marker cells
Standard Deviation 19.308
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+; FU;n=1,2,0,3,1,4
|
54.72 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
68.87 Percentage of CD marker cells
Standard Deviation 8.259
|
—
|
68.45 Percentage of CD marker cells
Standard Deviation 0.841
|
64.95 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
67.21 Percentage of CD marker cells
Standard Deviation 17.378
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+; USC;n=0,0,1,0,0,0
|
—
|
—
|
42.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+;D1pre; n=1,3,1,5,4,9
|
3.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.70 Percentage of CD marker cells
Standard Deviation 6.236
|
11.66 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.13 Percentage of CD marker cells
Standard Deviation 10.732
|
8.92 Percentage of CD marker cells
Standard Deviation 4.982
|
8.99 Percentage of CD marker cells
Standard Deviation 4.894
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+;D1;1 h;n=1,3,1,5,4,9
|
3.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.63 Percentage of CD marker cells
Standard Deviation 8.846
|
1.49 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.84 Percentage of CD marker cells
Standard Deviation 10.971
|
6.79 Percentage of CD marker cells
Standard Deviation 3.717
|
7.91 Percentage of CD marker cells
Standard Deviation 4.880
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+;D1;6 h;n=1,3,1,5,4,11
|
5.74 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.98 Percentage of CD marker cells
Standard Deviation 6.511
|
24.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.53 Percentage of CD marker cells
Standard Deviation 10.804
|
7.25 Percentage of CD marker cells
Standard Deviation 3.529
|
11.04 Percentage of CD marker cells
Standard Deviation 4.474
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
15.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.17 Percentage of CD marker cells
Standard Deviation 2.397
|
—
|
9.61 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+; D8; n=1,3,0,5,4,8
|
19.48 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.93 Percentage of CD marker cells
Standard Deviation 4.733
|
—
|
12.31 Percentage of CD marker cells
Standard Deviation 7.851
|
9.81 Percentage of CD marker cells
Standard Deviation 6.276
|
10.61 Percentage of CD marker cells
Standard Deviation 7.576
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+; D15;S1; n=1,3,1,5,4,9
|
10.68 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.32 Percentage of CD marker cells
Standard Deviation 2.680
|
76.14 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.84 Percentage of CD marker cells
Standard Deviation 7.608
|
8.13 Percentage of CD marker cells
Standard Deviation 4.504
|
10.75 Percentage of CD marker cells
Standard Deviation 6.692
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
84.64 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+; D29; n=1,3,1,4,4,8
|
11.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.24 Percentage of CD marker cells
Standard Deviation 3.455
|
54.47 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.88 Percentage of CD marker cells
Standard Deviation 12.246
|
10.30 Percentage of CD marker cells
Standard Deviation 6.320
|
10.79 Percentage of CD marker cells
Standard Deviation 4.881
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+; FU;n=1,2,0,3,1,4
|
6.07 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.19 Percentage of CD marker cells
Standard Deviation 6.124
|
—
|
27.28 Percentage of CD marker cells
Standard Deviation 11.058
|
5.11 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.44 Percentage of CD marker cells
Standard Deviation 10.953
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
11.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+;D1pre; n=1,3,1,5,4,9
|
3.22 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.33 Percentage of CD marker cells
Standard Deviation 5.965
|
11.31 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.68 Percentage of CD marker cells
Standard Deviation 10.738
|
8.62 Percentage of CD marker cells
Standard Deviation 4.781
|
8.55 Percentage of CD marker cells
Standard Deviation 4.996
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+;D1;1 h;n=1,3,1,5,4,9
|
3.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.15 Percentage of CD marker cells
Standard Deviation 8.408
|
1.49 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.33 Percentage of CD marker cells
Standard Deviation 10.922
|
6.42 Percentage of CD marker cells
Standard Deviation 3.287
|
7.43 Percentage of CD marker cells
Standard Deviation 4.929
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
|
5.63 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.29 Percentage of CD marker cells
Standard Deviation 5.756
|
24.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.00 Percentage of CD marker cells
Standard Deviation 10.573
|
6.89 Percentage of CD marker cells
Standard Deviation 3.217
|
10.03 Percentage of CD marker cells
Standard Deviation 4.618
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
15.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.02 Percentage of CD marker cells
Standard Deviation 2.220
|
—
|
9.57 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+; D8; n=1,3,0,5,4,8
|
17.91 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.29 Percentage of CD marker cells
Standard Deviation 3.881
|
—
|
11.95 Percentage of CD marker cells
Standard Deviation 7.603
|
9.36 Percentage of CD marker cells
Standard Deviation 5.904
|
9.58 Percentage of CD marker cells
Standard Deviation 6.752
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+; D15;S1 ; n=1,3,1,5,4,9
|
9.81 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.25 Percentage of CD marker cells
Standard Deviation 2.622
|
62.5 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.63 Percentage of CD marker cells
Standard Deviation 7.568
|
7.74 Percentage of CD marker cells
Standard Deviation 4.077
|
10.13 Percentage of CD marker cells
Standard Deviation 6.879
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
61.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+; D29; n=1,3,1,4,4,8
|
10.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.07 Percentage of CD marker cells
Standard Deviation 3.421
|
40.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.47 Percentage of CD marker cells
Standard Deviation 11.821
|
9.88 Percentage of CD marker cells
Standard Deviation 5.888
|
9.56 Percentage of CD marker cells
Standard Deviation 4.499
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+; FU;n=1,2,0,3,1,4
|
5.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.98 Percentage of CD marker cells
Standard Deviation 5.961
|
—
|
26.15 Percentage of CD marker cells
Standard Deviation 10.446
|
4.98 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.70 Percentage of CD marker cells
Standard Deviation 9.912
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
10.47 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-;D1pre; n=1,3,1,5,4,9
|
46.49 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
51.06 Percentage of CD marker cells
Standard Deviation 3.578
|
50.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.28 Percentage of CD marker cells
Standard Deviation 8.029
|
55.15 Percentage of CD marker cells
Standard Deviation 13.699
|
48.82 Percentage of CD marker cells
Standard Deviation 16.871
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9
|
47.13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
48.51 Percentage of CD marker cells
Standard Deviation 4.092
|
65.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
51.25 Percentage of CD marker cells
Standard Deviation 7.800
|
56.29 Percentage of CD marker cells
Standard Deviation 13.709
|
48.37 Percentage of CD marker cells
Standard Deviation 18.392
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
|
57.91 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
50.20 Percentage of CD marker cells
Standard Deviation 6.989
|
55.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
50.24 Percentage of CD marker cells
Standard Deviation 5.794
|
56.37 Percentage of CD marker cells
Standard Deviation 14.071
|
50.04 Percentage of CD marker cells
Standard Deviation 16.622
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
53.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
62.99 Percentage of CD marker cells
Standard Deviation 6.003
|
—
|
53.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-; D8; n=1,3,0,5,4,8
|
40.13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
50.00 Percentage of CD marker cells
Standard Deviation 5.550
|
—
|
53.02 Percentage of CD marker cells
Standard Deviation 7.641
|
56.37 Percentage of CD marker cells
Standard Deviation 8.661
|
41.72 Percentage of CD marker cells
Standard Deviation 11.909
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+; D2; n=0,0,1,2,0,1
|
—
|
—
|
71.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
77.60 Percentage of CD marker cells
Standard Deviation 7.898
|
—
|
73.16 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-; D15; S1; n=1,3,1,5,4,9
|
44.09 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
60.67 Percentage of CD marker cells
Standard Deviation 5.732
|
10.23 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
55.45 Percentage of CD marker cells
Standard Deviation 4.502
|
50.72 Percentage of CD marker cells
Standard Deviation 6.589
|
43.25 Percentage of CD marker cells
Standard Deviation 18.831
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-; D15; S2;n=0, 0, 1, 0, 0, 0
|
—
|
—
|
6.15 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-; D29; n=1,3,1,4,4,8
|
50.26 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
58.89 Percentage of CD marker cells
Standard Deviation 0.756
|
12.29 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
50.05 Percentage of CD marker cells
Standard Deviation 6.415
|
54.00 Percentage of CD marker cells
Standard Deviation 11.624
|
44.11 Percentage of CD marker cells
Standard Deviation 17.898
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+; D8; n=1,3,0,5,4,8
|
63.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
65.38 Percentage of CD marker cells
Standard Deviation 2.682
|
—
|
71.51 Percentage of CD marker cells
Standard Deviation 5.945
|
69.15 Percentage of CD marker cells
Standard Deviation 2.032
|
59.81 Percentage of CD marker cells
Standard Deviation 14.230
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-; FU;n=1,2,0,3,1,4
|
48.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
57.90 Percentage of CD marker cells
Standard Deviation 2.298
|
—
|
42.29 Percentage of CD marker cells
Standard Deviation 9.606
|
59.97 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
55.52 Percentage of CD marker cells
Standard Deviation 16.825
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69+CD107-; USC;n=0,0,1,0,0,0
|
—
|
—
|
31.83 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+; D15;S2;n=0,0,1,0,0,0
|
—
|
—
|
69.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+;D1pre; n=1,3,1,5,4,9
|
0.06 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.36 Percentage of CD marker cells
Standard Deviation 0.277
|
0.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.45 Percentage of CD marker cells
Standard Deviation 0.579
|
0.30 Percentage of CD marker cells
Standard Deviation 0.324
|
0.44 Percentage of CD marker cells
Standard Deviation 0.537
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+; D29; n=1,3,1,4,4,8
|
68.47 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
72.13 Percentage of CD marker cells
Standard Deviation 0.599
|
52.66 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
68.07 Percentage of CD marker cells
Standard Deviation 4.666
|
70.42 Percentage of CD marker cells
Standard Deviation 3.658
|
60.96 Percentage of CD marker cells
Standard Deviation 16.314
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9
|
0.13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.47 Percentage of CD marker cells
Standard Deviation 0.451
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.50 Percentage of CD marker cells
Standard Deviation 0.615
|
0.36 Percentage of CD marker cells
Standard Deviation 0.477
|
0.48 Percentage of CD marker cells
Standard Deviation 0.459
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+; FU;n=1,2,0,3,1,4
|
67.97 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
74.76 Percentage of CD marker cells
Standard Deviation 3.903
|
—
|
74.36 Percentage of CD marker cells
Standard Deviation 3.927
|
70.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
70.63 Percentage of CD marker cells
Standard Deviation 13.052
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
|
0.11 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.69 Percentage of CD marker cells
Standard Deviation 0.777
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.54 Percentage of CD marker cells
Standard Deviation 0.844
|
0.36 Percentage of CD marker cells
Standard Deviation 0.349
|
1.01 Percentage of CD marker cells
Standard Deviation 1.233
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.15 Percentage of CD marker cells
Standard Deviation 0.177
|
—
|
0.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+; USC;n=0,0,1,0,0,0
|
—
|
—
|
45.15 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+; D8; n=1,3,0,5,4,8
|
1.57 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.64 Percentage of CD marker cells
Standard Deviation 0.861
|
—
|
0.35 Percentage of CD marker cells
Standard Deviation 3.392
|
0.45 Percentage of CD marker cells
Standard Deviation 0.458
|
1.04 Percentage of CD marker cells
Standard Deviation 1.201
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+;D1pre; n=1,3,1,5,4,9
|
9.25 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.58 Percentage of CD marker cells
Standard Deviation 6.553
|
17.31 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.38 Percentage of CD marker cells
Standard Deviation 10.840
|
19.50 Percentage of CD marker cells
Standard Deviation 5.678
|
12.96 Percentage of CD marker cells
Standard Deviation 7.622
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+;D1;1 h;n=1,3,1,5,4,9
|
11.02 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.64 Percentage of CD marker cells
Standard Deviation 7.885
|
4.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.87 Percentage of CD marker cells
Standard Deviation 10.264
|
17.86 Percentage of CD marker cells
Standard Deviation 7.915
|
12.10 Percentage of CD marker cells
Standard Deviation 9.816
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+; D15; S1; n=1,3,1,5,4,9
|
0.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.07 Percentage of CD marker cells
Standard Deviation 0.059
|
13.64 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.21 Percentage of CD marker cells
Standard Deviation 0.187
|
0.39 Percentage of CD marker cells
Standard Deviation 0.439
|
0.62 Percentage of CD marker cells
Standard Deviation 0.460
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+;D1;6 h;n=1,3,1,5,4,11
|
13.88 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.21 Percentage of CD marker cells
Standard Deviation 5.668
|
35.14 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.61 Percentage of CD marker cells
Standard Deviation 12.241
|
17.74 Percentage of CD marker cells
Standard Deviation 6.679
|
14.58 Percentage of CD marker cells
Standard Deviation 7.973
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
23.43 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+; D29; n=1,3,1,4,4,8
|
1.34 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.17 Percentage of CD marker cells
Standard Deviation 0.042
|
13.97 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.41 Percentage of CD marker cells
Standard Deviation 0.476
|
0.42 Percentage of CD marker cells
Standard Deviation 0.449
|
1.22 Percentage of CD marker cells
Standard Deviation 1.608
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
25.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.03 Percentage of CD marker cells
Standard Deviation 4.907
|
—
|
15.65 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+; FU;n=1,2,0,3,1,4
|
0.15 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.23 Percentage of CD marker cells
Standard Deviation 0.163
|
—
|
1.13 Percentage of CD marker cells
Standard Deviation 0.705
|
0.13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.75 Percentage of CD marker cells
Standard Deviation 1.090
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+; D8; n=1,3,0,5,4,8
|
37.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.18 Percentage of CD marker cells
Standard Deviation 3.660
|
—
|
24.12 Percentage of CD marker cells
Standard Deviation 11.200
|
19.58 Percentage of CD marker cells
Standard Deviation 10.034
|
13.53 Percentage of CD marker cells
Standard Deviation 7.177
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+; D15; S1;n=1,3,1,5,4,9
|
20.58 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.59 Percentage of CD marker cells
Standard Deviation 2.973
|
93.55 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.11 Percentage of CD marker cells
Standard Deviation 14.964
|
18.52 Percentage of CD marker cells
Standard Deviation 6.515
|
14.52 Percentage of CD marker cells
Standard Deviation 11.560
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+; D15;S2;n=0,0,1,0,0,0
|
—
|
—
|
90.12 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+; D29; n=1,3,1,4,4,8
|
44.48 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.53 Percentage of CD marker cells
Standard Deviation 2.105
|
66.27 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.44 Percentage of CD marker cells
Standard Deviation 12.685
|
22.28 Percentage of CD marker cells
Standard Deviation 10.800
|
16.01 Percentage of CD marker cells
Standard Deviation 7.377
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
1.16 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-;D1pre; n=1,3,1,5,4,9
|
50.23 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
35.23 Percentage of CD marker cells
Standard Deviation 2.664
|
37.81 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
34.58 Percentage of CD marker cells
Standard Deviation 9.638
|
35.93 Percentage of CD marker cells
Standard Deviation 9.242
|
42.20 Percentage of CD marker cells
Standard Deviation 19.537
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+; FU;n=1,2,0,3,1,4
|
21.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.00 Percentage of CD marker cells
Standard Deviation 7.545
|
—
|
34.50 Percentage of CD marker cells
Standard Deviation 27.190
|
20.65 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.54 Percentage of CD marker cells
Standard Deviation 20.530
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9
|
49.71 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
38.87 Percentage of CD marker cells
Standard Deviation 5.156
|
32.84 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
35.91 Percentage of CD marker cells
Standard Deviation 7.854
|
36.93 Percentage of CD marker cells
Standard Deviation 12.789
|
43.72 Percentage of CD marker cells
Standard Deviation 21.074
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
13.91 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+;D1pre; n=1,3,1,5,4,9
|
8.95 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.82 Percentage of CD marker cells
Standard Deviation 6.136
|
16.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.35 Percentage of CD marker cells
Standard Deviation 10.595
|
18.89 Percentage of CD marker cells
Standard Deviation 5.513
|
12.42 Percentage of CD marker cells
Standard Deviation 7.519
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
|
36.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
37.83 Percentage of CD marker cells
Standard Deviation 3.625
|
20.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
37.23 Percentage of CD marker cells
Standard Deviation 7.810
|
36.38 Percentage of CD marker cells
Standard Deviation 12.700
|
38.92 Percentage of CD marker cells
Standard Deviation 18.214
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
31.39 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
30.85 Percentage of CD marker cells
Standard Deviation 3.606
|
—
|
37.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-; D8; n=1,3,0,5,4,8
|
40.39 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
40.07 Percentage of CD marker cells
Standard Deviation 5.758
|
—
|
34.67 Percentage of CD marker cells
Standard Deviation 2.320
|
33.83 Percentage of CD marker cells
Standard Deviation 6.576
|
47.67 Percentage of CD marker cells
Standard Deviation 13.646
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+;D1;1 h;n=1,3,1,5,4,9
|
10.13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.60 Percentage of CD marker cells
Standard Deviation 7.232
|
4.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.63 Percentage of CD marker cells
Standard Deviation 10.069
|
17.10 Percentage of CD marker cells
Standard Deviation 7.592
|
11.51 Percentage of CD marker cells
Standard Deviation 9.671
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
|
13.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.92 Percentage of CD marker cells
Standard Deviation 4.681
|
35.14 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.61 Percentage of CD marker cells
Standard Deviation 11.463
|
16.83 Percentage of CD marker cells
Standard Deviation 6.502
|
13.49 Percentage of CD marker cells
Standard Deviation 8.242
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-; D15;S1; n=1,3,1,5,4,9
|
45.24 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
35.01 Percentage of CD marker cells
Standard Deviation 3.981
|
13.64 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
34.71 Percentage of CD marker cells
Standard Deviation 6.524
|
41.15 Percentage of CD marker cells
Standard Deviation 3.409
|
46.00 Percentage of CD marker cells
Standard Deviation 21.556
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
25.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.67 Percentage of CD marker cells
Standard Deviation 4.391
|
—
|
15.59 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-; D15; S2;n=0,0,1,0,0,0
|
—
|
—
|
9.2 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-; D29; n=1,3,1,4,4,8
|
38.12 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
31.87 Percentage of CD marker cells
Standard Deviation 4.127
|
33.24 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
38.07 Percentage of CD marker cells
Standard Deviation 6.801
|
35.70 Percentage of CD marker cells
Standard Deviation 5.601
|
45.10 Percentage of CD marker cells
Standard Deviation 18.361
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+; D8; n=1,3,0,5,4,8
|
33.65 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.86 Percentage of CD marker cells
Standard Deviation 1.989
|
—
|
23.15 Percentage of CD marker cells
Standard Deviation 10.176
|
18.62 Percentage of CD marker cells
Standard Deviation 9.229
|
12.58 Percentage of CD marker cells
Standard Deviation 6.811
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-; FU;n=1,2,0,3,1,4
|
45.14 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
30.91 Percentage of CD marker cells
Standard Deviation 8.422
|
—
|
30.43 Percentage of CD marker cells
Standard Deviation 1.483
|
34.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
32.05 Percentage of CD marker cells
Standard Deviation 17.570
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD69-CD107-; USC;n=0,0,1,0,0,0
|
—
|
—
|
56.55 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+;D1pre; n=1,3,1,5,4,9
|
47.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
61.18 Percentage of CD marker cells
Standard Deviation 3.198
|
63.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
60.39 Percentage of CD marker cells
Standard Deviation 9.372
|
58.78 Percentage of CD marker cells
Standard Deviation 9.546
|
52.12 Percentage of CD marker cells
Standard Deviation 20.035
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+;D1;1 h;n=1,3,1,5,4,9
|
49.15 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
58.34 Percentage of CD marker cells
Standard Deviation 5.829
|
67.19 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
60.93 Percentage of CD marker cells
Standard Deviation 7.196
|
59.04 Percentage of CD marker cells
Standard Deviation 12.906
|
51.86 Percentage of CD marker cells
Standard Deviation 22.844
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+; D15;S1; n=1,3,1,5,4,9
|
19.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.35 Percentage of CD marker cells
Standard Deviation 2.815
|
64.52 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.62 Percentage of CD marker cells
Standard Deviation 14.511
|
17.46 Percentage of CD marker cells
Standard Deviation 5.818
|
13.79 Percentage of CD marker cells
Standard Deviation 11.461
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+;D1;6 h;n=1,3,1,5,4,11
|
62.61 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
60.24 Percentage of CD marker cells
Standard Deviation 3.832
|
77.59 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
58.97 Percentage of CD marker cells
Standard Deviation 6.452
|
59.18 Percentage of CD marker cells
Standard Deviation 13.744
|
56.19 Percentage of CD marker cells
Standard Deviation 18.029
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
66.74 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+; D2; n=0,0,1,2,0,1
|
—
|
—
|
67.11 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
63.36 Percentage of CD marker cells
Standard Deviation 5.169
|
—
|
51.49 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+; D8; n=1,3,0,5,4,8
|
57.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
56.36 Percentage of CD marker cells
Standard Deviation 7.227
|
—
|
61.41 Percentage of CD marker cells
Standard Deviation 3.385
|
64.59 Percentage of CD marker cells
Standard Deviation 10.317
|
42.80 Percentage of CD marker cells
Standard Deviation 13.006
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+; D29; n=1,3,1,4,4,8
|
36.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.16 Percentage of CD marker cells
Standard Deviation 2.172
|
44.97 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.79 Percentage of CD marker cells
Standard Deviation 12.221
|
21.18 Percentage of CD marker cells
Standard Deviation 9.942
|
14.79 Percentage of CD marker cells
Standard Deviation 7.086
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+; FU;n=1,2,0,3,1,4
|
20.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.43 Percentage of CD marker cells
Standard Deviation 7.177
|
—
|
33.05 Percentage of CD marker cells
Standard Deviation 25.896
|
20.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.91 Percentage of CD marker cells
Standard Deviation 18.370
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+; D15; S1;n=1,3,1,5,4,9
|
47.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
64.16 Percentage of CD marker cells
Standard Deviation 6.272
|
75.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
61.57 Percentage of CD marker cells
Standard Deviation 4.769
|
53.99 Percentage of CD marker cells
Standard Deviation 7.004
|
49.92 Percentage of CD marker cells
Standard Deviation 22.128
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+CD69+CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
12.34 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+; D15; S2;n=0,0,1,0,0,0
|
—
|
—
|
66.87 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+; D29; n=1,3,1,4,4,8
|
59.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
66.23 Percentage of CD marker cells
Standard Deviation 5.538
|
54.82 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
57.72 Percentage of CD marker cells
Standard Deviation 3.694
|
59.41 Percentage of CD marker cells
Standard Deviation 7.751
|
50.71 Percentage of CD marker cells
Standard Deviation 19.479
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+; FU;n=1,2,0,3,1,4
|
52.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
65.54 Percentage of CD marker cells
Standard Deviation 8.811
|
—
|
62.68 Percentage of CD marker cells
Standard Deviation 3.581
|
64.72 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
59.43 Percentage of CD marker cells
Standard Deviation 17.448
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+; USC;n=0,0,1,0,0,0
|
—
|
—
|
41.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+;D1pre; n=1,3,1,5,4,9
|
1.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.52 Percentage of CD marker cells
Standard Deviation 6.264
|
8.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.13 Percentage of CD marker cells
Standard Deviation 7.030
|
9.40 Percentage of CD marker cells
Standard Deviation 9.095
|
8.89 Percentage of CD marker cells
Standard Deviation 7.406
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+;D1;1 h;n=1,3,1,5,4,9
|
2.05 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.13 Percentage of CD marker cells
Standard Deviation 9.350
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.77 Percentage of CD marker cells
Standard Deviation 6.304
|
10.14 Percentage of CD marker cells
Standard Deviation 11.064
|
5.52 Percentage of CD marker cells
Standard Deviation 3.023
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+;D1;6 h;n=1,3,1,5,4,11
|
4.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.43 Percentage of CD marker cells
Standard Deviation 6.165
|
14.66 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.25 Percentage of CD marker cells
Standard Deviation 7.708
|
11.10 Percentage of CD marker cells
Standard Deviation 12.927
|
8.49 Percentage of CD marker cells
Standard Deviation 3.930
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
7.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.06 Percentage of CD marker cells
Standard Deviation 12.183
|
—
|
12.25 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+; D8; n=1,3,0,5,4,8
|
16.59 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.43 Percentage of CD marker cells
Standard Deviation 4.942
|
—
|
8.44 Percentage of CD marker cells
Standard Deviation 5.762
|
6.89 Percentage of CD marker cells
Standard Deviation 3.550
|
7.20 Percentage of CD marker cells
Standard Deviation 3.406
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+; D15; S1;n=1,3,1,5,4,9
|
8.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.31 Percentage of CD marker cells
Standard Deviation 2.868
|
67.24 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.32 Percentage of CD marker cells
Standard Deviation 4.700
|
6.66 Percentage of CD marker cells
Standard Deviation 4.113
|
10.03 Percentage of CD marker cells
Standard Deviation 7.687
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
79.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+; D29; n=1,3,1,4,4,8
|
6.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.33 Percentage of CD marker cells
Standard Deviation 3.967
|
45.69 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.99 Percentage of CD marker cells
Standard Deviation 2.600
|
8.29 Percentage of CD marker cells
Standard Deviation 3.475
|
8.07 Percentage of CD marker cells
Standard Deviation 5.728
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+; FU;n=1,2,0,3,1,4
|
3.99 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.22 Percentage of CD marker cells
Standard Deviation 14.015
|
—
|
16.79 Percentage of CD marker cells
Standard Deviation 8.978
|
4.78 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.10 Percentage of CD marker cells
Standard Deviation 11.466
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
10.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+;D1pre; n=1,3,1,5,4,9
|
1.88 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.34 Percentage of CD marker cells
Standard Deviation 6.086
|
8.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.66 Percentage of CD marker cells
Standard Deviation 6.705
|
8.70 Percentage of CD marker cells
Standard Deviation 8.036
|
8.49 Percentage of CD marker cells
Standard Deviation 7.511
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+;D1;1 h;n=1,3,1,5,4,9
|
2.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.84 Percentage of CD marker cells
Standard Deviation 8.957
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.39 Percentage of CD marker cells
Standard Deviation 6.132
|
9.37 Percentage of CD marker cells
Standard Deviation 9.954
|
5.08 Percentage of CD marker cells
Standard Deviation 3.208
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
|
4.69 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.99 Percentage of CD marker cells
Standard Deviation 5.509
|
14.66 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.81 Percentage of CD marker cells
Standard Deviation 7.518
|
10.26 Percentage of CD marker cells
Standard Deviation 11.433
|
7.64 Percentage of CD marker cells
Standard Deviation 3.879
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
7.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.45 Percentage of CD marker cells
Standard Deviation 10.684
|
—
|
11.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+; D8; n=1,3,0,5,4,8
|
15.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.16 Percentage of CD marker cells
Standard Deviation 4.542
|
—
|
8.22 Percentage of CD marker cells
Standard Deviation 5.569
|
6.68 Percentage of CD marker cells
Standard Deviation 3.439
|
6.35 Percentage of CD marker cells
Standard Deviation 3.062
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+; D15; S1;n=1,3,1,5,4,9
|
7.37 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.28 Percentage of CD marker cells
Standard Deviation 2.851
|
62.07 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.09 Percentage of CD marker cells
Standard Deviation 4.543
|
6.42 Percentage of CD marker cells
Standard Deviation 3.978
|
9.27 Percentage of CD marker cells
Standard Deviation 7.216
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
58.06 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+; D29; n=1,3,1,4,4,8
|
5.81 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.26 Percentage of CD marker cells
Standard Deviation 3.913
|
38.58 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.39 Percentage of CD marker cells
Standard Deviation 1.938
|
8.03 Percentage of CD marker cells
Standard Deviation 3.389
|
6.92 Percentage of CD marker cells
Standard Deviation 4.718
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+; FU;n=1,2,0,3,1,4
|
3.94 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.93 Percentage of CD marker cells
Standard Deviation 13.598
|
—
|
16.09 Percentage of CD marker cells
Standard Deviation 8.306
|
4.63 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.87 Percentage of CD marker cells
Standard Deviation 10.444
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
9.71 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-;D1pre; n=1,3,1,5,4,9
|
46.02 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.84 Percentage of CD marker cells
Standard Deviation 2.952
|
55.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
51.72 Percentage of CD marker cells
Standard Deviation 7.637
|
50.08 Percentage of CD marker cells
Standard Deviation 9.719
|
43.63 Percentage of CD marker cells
Standard Deviation 15.780
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-;D1;1 h;n=1,3,1,5,4,9
|
47.12 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
49.48 Percentage of CD marker cells
Standard Deviation 3.288
|
67.19 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.53 Percentage of CD marker cells
Standard Deviation 6.408
|
49.68 Percentage of CD marker cells
Standard Deviation 9.756
|
46.78 Percentage of CD marker cells
Standard Deviation 20.420
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
|
57.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.25 Percentage of CD marker cells
Standard Deviation 6.443
|
62.93 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
49.16 Percentage of CD marker cells
Standard Deviation 4.649
|
48.93 Percentage of CD marker cells
Standard Deviation 11.819
|
48.55 Percentage of CD marker cells
Standard Deviation 16.115
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
59.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
42.91 Percentage of CD marker cells
Standard Deviation 5.515
|
—
|
39.59 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-; D8; n=1,3,0,5,4,8
|
41.88 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
51.21 Percentage of CD marker cells
Standard Deviation 6.451
|
—
|
53.19 Percentage of CD marker cells
Standard Deviation 5.196
|
57.91 Percentage of CD marker cells
Standard Deviation 9.965
|
36.45 Percentage of CD marker cells
Standard Deviation 12.237
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-; D15;S1; n=1,3,1,5,4,9
|
40.25 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
59.88 Percentage of CD marker cells
Standard Deviation 3.546
|
13.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
54.48 Percentage of CD marker cells
Standard Deviation 6.572
|
47.58 Percentage of CD marker cells
Standard Deviation 6.986
|
40.65 Percentage of CD marker cells
Standard Deviation 18.749
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
8.81 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-; D29; n=1,3,1,4,4,8
|
53.36 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
60.98 Percentage of CD marker cells
Standard Deviation 1.681
|
16.24 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
50.33 Percentage of CD marker cells
Standard Deviation 5.623
|
51.37 Percentage of CD marker cells
Standard Deviation 5.812
|
43.79 Percentage of CD marker cells
Standard Deviation 19.299
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-; FU;n=1,2,0,3,1,4
|
48.95 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
53.62 Percentage of CD marker cells
Standard Deviation 4.794
|
—
|
46.59 Percentage of CD marker cells
Standard Deviation 4.968
|
60.09 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
44.55 Percentage of CD marker cells
Standard Deviation 12.109
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69+CD107-; USC;n=0,0,1,0,0,0
|
—
|
—
|
31.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+;D1pre; n=1,3,1,5,4,9
|
0.01 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.17 Percentage of CD marker cells
Standard Deviation 0.180
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.47 Percentage of CD marker cells
Standard Deviation 0.607
|
0.70 Percentage of CD marker cells
Standard Deviation 1.089
|
0.41 Percentage of CD marker cells
Standard Deviation 0.541
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+;D1;1 h;n=1,3,1,5,4,9
|
0.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.27 Percentage of CD marker cells
Standard Deviation 0.414
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.38 Percentage of CD marker cells
Standard Deviation 0.526
|
0.77 Percentage of CD marker cells
Standard Deviation 1.174
|
0.43 Percentage of CD marker cells
Standard Deviation 0.496
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
|
0.11 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.44 Percentage of CD marker cells
Standard Deviation 0.691
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.44 Percentage of CD marker cells
Standard Deviation 0.695
|
0.85 Percentage of CD marker cells
Standard Deviation 1.537
|
0.85 Percentage of CD marker cells
Standard Deviation 1.277
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.62 Percentage of CD marker cells
Standard Deviation 1.492
|
—
|
0.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+; D8; n=1,3,0,5,4,8
|
1.19 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.27 Percentage of CD marker cells
Standard Deviation 0.406
|
—
|
0.22 Percentage of CD marker cells
Standard Deviation 0.239
|
0.21 Percentage of CD marker cells
Standard Deviation 0.194
|
0.85 Percentage of CD marker cells
Standard Deviation 0.855
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+; D15;S1; n=1,3,1,5,4,9
|
0.66 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.02 Percentage of CD marker cells
Standard Deviation 0.020
|
5.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.23 Percentage of CD marker cells
Standard Deviation 0.217
|
0.25 Percentage of CD marker cells
Standard Deviation 0.179
|
0.76 Percentage of CD marker cells
Standard Deviation 0.966
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
21.74 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+; D29; n=1,3,1,4,4,8
|
0.24 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.08 Percentage of CD marker cells
Standard Deviation 0.057
|
7.11 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.60 Percentage of CD marker cells
Standard Deviation 0.787
|
0.23 Percentage of CD marker cells
Standard Deviation 0.117
|
1.15 Percentage of CD marker cells
Standard Deviation 1.764
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+; FU;n=1,2,0,3,1,4
|
0.05 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.30 Percentage of CD marker cells
Standard Deviation 0.417
|
—
|
0.70 Percentage of CD marker cells
Standard Deviation 0.729
|
0.15 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.22 Percentage of CD marker cells
Standard Deviation 1.319
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107+; USC;n=0,0,1,0,0,0
|
—
|
—
|
0.91 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-;D1pre; n=1,3,1,5,4,9
|
52.08 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
38.64 Percentage of CD marker cells
Standard Deviation 3.370
|
36.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
39.14 Percentage of CD marker cells
Standard Deviation 9.186
|
40.53 Percentage of CD marker cells
Standard Deviation 9.843
|
47.48 Percentage of CD marker cells
Standard Deviation 19.639
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-;D1;1 h;n=1,3,1,5,4,9
|
50.83 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
41.39 Percentage of CD marker cells
Standard Deviation 6.239
|
32.81 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
38.69 Percentage of CD marker cells
Standard Deviation 6.983
|
40.19 Percentage of CD marker cells
Standard Deviation 13.401
|
47.70 Percentage of CD marker cells
Standard Deviation 22.541
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
|
37.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
39.32 Percentage of CD marker cells
Standard Deviation 4.165
|
22.41 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
40.59 Percentage of CD marker cells
Standard Deviation 6.401
|
39.98 Percentage of CD marker cells
Standard Deviation 14.362
|
42.96 Percentage of CD marker cells
Standard Deviation 17.217
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
32.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
35.03 Percentage of CD marker cells
Standard Deviation 6.661
|
—
|
48.16 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-; D8; n=1,3,0,5,4,8
|
41.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
43.36 Percentage of CD marker cells
Standard Deviation 7.367
|
—
|
38.37 Percentage of CD marker cells
Standard Deviation 3.532
|
35.20 Percentage of CD marker cells
Standard Deviation 10.279
|
56.36 Percentage of CD marker cells
Standard Deviation 12.433
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-; D15;S1;n=1,3,1,5,4,9
|
51.72 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
35.82 Percentage of CD marker cells
Standard Deviation 6.285
|
18.97 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
38.20 Percentage of CD marker cells
Standard Deviation 4.657
|
45.76 Percentage of CD marker cells
Standard Deviation 6.941
|
49.32 Percentage of CD marker cells
Standard Deviation 21.812
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
11.4 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-; D29; n=1,3,1,4,4,8
|
40.59 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
33.69 Percentage of CD marker cells
Standard Deviation 5.590
|
38.07 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
41.69 Percentage of CD marker cells
Standard Deviation 3.048
|
40.37 Percentage of CD marker cells
Standard Deviation 7.766
|
48.14 Percentage of CD marker cells
Standard Deviation 18.661
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-; FU;n=1,2,0,3,1,4
|
47.06 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
34.17 Percentage of CD marker cells
Standard Deviation 9.228
|
—
|
36.61 Percentage of CD marker cells
Standard Deviation 4.300
|
35.13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
39.35 Percentage of CD marker cells
Standard Deviation 17.631
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-CD69-CD107-; USC;n=0,0,1,0,0,0
|
—
|
—
|
58.05 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+;D1pre; n=1,3,1,5,4,9
|
75.76 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
67.04 Percentage of CD marker cells
Standard Deviation 8.518
|
84.75 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
70.41 Percentage of CD marker cells
Standard Deviation 7.715
|
66.51 Percentage of CD marker cells
Standard Deviation 16.098
|
60.06 Percentage of CD marker cells
Standard Deviation 14.370
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+;D1;1 h;n=1,3,1,5,4,9
|
80.05 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
66.03 Percentage of CD marker cells
Standard Deviation 12.856
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
72.80 Percentage of CD marker cells
Standard Deviation 9.542
|
67.42 Percentage of CD marker cells
Standard Deviation 15.190
|
61.79 Percentage of CD marker cells
Standard Deviation 14.941
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+;D1;6 h;n=1,3,1,5,4,11
|
78.69 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
69.97 Percentage of CD marker cells
Standard Deviation 8.412
|
84.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
68.55 Percentage of CD marker cells
Standard Deviation 5.810
|
63.22 Percentage of CD marker cells
Standard Deviation 18.089
|
66.22 Percentage of CD marker cells
Standard Deviation 20.094
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+; D2; n=0,0,1,2,0,1
|
—
|
—
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
71.53 Percentage of CD marker cells
Standard Deviation 0.721
|
—
|
58.57 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+; D8; n=1,3,0,5,4,8
|
72.44 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
62.85 Percentage of CD marker cells
Standard Deviation 5.952
|
—
|
70.60 Percentage of CD marker cells
Standard Deviation 5.653
|
66.95 Percentage of CD marker cells
Standard Deviation 20.328
|
52.90 Percentage of CD marker cells
Standard Deviation 52.90
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+; D15;S1; n=1,3,1,5,4,9
|
71.85 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
64.28 Percentage of CD marker cells
Standard Deviation 7.449
|
89.47 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
70.07 Percentage of CD marker cells
Standard Deviation 6.942
|
61.50 Percentage of CD marker cells
Standard Deviation 12.596
|
61.77 Percentage of CD marker cells
Standard Deviation 61.77
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+; D15;S2;n=0,0,1,0,0,0
|
—
|
—
|
85.95 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+; D29; n=1,3,1,4,4,8
|
74.65 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
72.22 Percentage of CD marker cells
Standard Deviation 17.828
|
66.18 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
68.83 Percentage of CD marker cells
Standard Deviation 5.767
|
65.80 Percentage of CD marker cells
Standard Deviation 7.211
|
61.49 Percentage of CD marker cells
Standard Deviation 61.49
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+; FU;n=1,2,0,3,1,4
|
74.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
68.44 Percentage of CD marker cells
Standard Deviation 5.268
|
—
|
73.60 Percentage of CD marker cells
Standard Deviation 7.363
|
73.22 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
70.54 Percentage of CD marker cells
Standard Deviation 70.54
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+CD69+; USC;n=0,0,1,0,0,0
|
—
|
—
|
60.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+;D1pre; n=1,3,1,5,4,9
|
99.66 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.57 Percentage of CD marker cells
Standard Deviation 0.371
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.27 Percentage of CD marker cells
Standard Deviation 0.308
|
99.19 Percentage of CD marker cells
Standard Deviation 1.046
|
99.39 Percentage of CD marker cells
Standard Deviation 0.407
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+;D1;1 h;n=1,3,1,5,4,9
|
99.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.54 Percentage of CD marker cells
Standard Deviation 0.204
|
99.55 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.42 Percentage of CD marker cells
Standard Deviation 0.202
|
99.51 Percentage of CD marker cells
Standard Deviation 0.658
|
99.37 Percentage of CD marker cells
Standard Deviation 0.725
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+;D1;6 h;n=1,3,1,5,4,11
|
99.45 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.19 Percentage of CD marker cells
Standard Deviation 0.239
|
99.78 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.28 Percentage of CD marker cells
Standard Deviation 0.393
|
99.11 Percentage of CD marker cells
Standard Deviation 1.442
|
99.24 Percentage of CD marker cells
Standard Deviation 0.942
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+; D2; n=0,0,1,2,0,1
|
—
|
—
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.16 Percentage of CD marker cells
Standard Deviation 1.018
|
—
|
99.06 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+; D8; n=1,3,0,5,4,8
|
99.41 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.49 Percentage of CD marker cells
Standard Deviation 0.297
|
—
|
99.15 Percentage of CD marker cells
Standard Deviation 0.763
|
99.78 Percentage of CD marker cells
Standard Deviation 0.241
|
98.64 Percentage of CD marker cells
Standard Deviation 1.993
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+; D15; S1; n=1,3,1,5,4,9
|
99.37 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.70 Percentage of CD marker cells
Standard Deviation 0.145
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.71 Percentage of CD marker cells
Standard Deviation 0.311
|
99.50 Percentage of CD marker cells
Standard Deviation 0.435
|
97.67 Percentage of CD marker cells
Standard Deviation 3.444
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
99.74 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+; D29; n=1,3,1,4,4,8
|
99.66 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.61 Percentage of CD marker cells
Standard Deviation 0.391
|
98.85 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.53 Percentage of CD marker cells
Standard Deviation 0.379
|
99.68 Percentage of CD marker cells
Standard Deviation 0.225
|
98.98 Percentage of CD marker cells
Standard Deviation 1.950
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+; FU;n=1,2,0,3,1,4
|
99.71 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.66 Percentage of CD marker cells
Standard Deviation 0.028
|
—
|
99.62 Percentage of CD marker cells
Standard Deviation 0.219
|
99.47 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.65 Percentage of CD marker cells
Standard Deviation 0.288
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+CD69+; USC;n=0,0,1,0,0,0
|
—
|
—
|
96.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; D8; n=1, 3, 0, 5, 4, 8
|
13.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.43 Percentage of CD marker cells
Standard Deviation 10.625
|
—
|
6.16 Percentage of CD marker cells
Standard Deviation 2.574
|
11.10 Percentage of CD marker cells
Standard Deviation 4.808
|
12.33 Percentage of CD marker cells
Standard Deviation 7.733
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; D1; pre; n=1, 3, 1, 5, 4, 9
|
99.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.83 Percentage of CD marker cells
Standard Deviation 0.058
|
99.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.76 Percentage of CD marker cells
Standard Deviation 0.434
|
99.93 Percentage of CD marker cells
Standard Deviation 0.050
|
101.57 Percentage of CD marker cells
Standard Deviation 6.268
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; D1; 1 h; n=1, 3, 1, 5, 4, 9
|
99.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.87 Percentage of CD marker cells
Standard Deviation 0.058
|
99.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.76 Percentage of CD marker cells
Standard Deviation 0.434
|
99.93 Percentage of CD marker cells
Standard Deviation 0.050
|
101.13 Percentage of CD marker cells
Standard Deviation 4.656
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; D1; 6 h; n=1, 3, 1, 5, 4, 11
|
99.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.83 Percentage of CD marker cells
Standard Deviation 0.058
|
99.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.8 Percentage of CD marker cells
Standard Deviation 0.255
|
99.93 Percentage of CD marker cells
Standard Deviation 0.096
|
101.02 Percentage of CD marker cells
Standard Deviation 3.978
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
99.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.7 Percentage of CD marker cells
Standard Deviation 0.424
|
—
|
99.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; D8; n=1, 3, 0, 5, 4, 8
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.87 Percentage of CD marker cells
Standard Deviation 0.058
|
—
|
99.4 Percentage of CD marker cells
Standard Deviation 1.231
|
99.80 Percentage of CD marker cells
Standard Deviation 0.400
|
99.75 Percentage of CD marker cells
Standard Deviation 0.576
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; D15;S1; n=1, 3, 1, 5, 4, 9
|
99.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.90 Percentage of CD marker cells
Standard Deviation 0.000
|
99.9 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.78 Percentage of CD marker cells
Standard Deviation 0.327
|
99.78 Percentage of CD marker cells
Standard Deviation 0.320
|
100.33 Percentage of CD marker cells
Standard Deviation 2.495
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
99.8 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; follow-up (FU); n=1, 2, 0, 3, 1, 4
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
99.85 Percentage of CD marker cells
Standard Deviation 0.071
|
—
|
99.63 Percentage of CD marker cells
Standard Deviation 0.551
|
99.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
101.60 Percentage of CD marker cells
Standard Deviation 4.827
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+; unscheduled (USC); n=0, 0, 1, 0, 0, 0
|
—
|
—
|
100.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; D1; pre;n=1, 3, 1, 5, 4, 9
|
62.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
69.00 Percentage of CD marker cells
Standard Deviation 13.313
|
58.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
86.88 Percentage of CD marker cells
Standard Deviation 2.580
|
71.98 Percentage of CD marker cells
Standard Deviation 10.832
|
72.91 Percentage of CD marker cells
Standard Deviation 8.027
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; D1; 1 h; n=1, 3, 1, 5, 4, 9
|
76.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
73.83 Percentage of CD marker cells
Standard Deviation 9.646
|
57.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
87.08 Percentage of CD marker cells
Standard Deviation 2.153
|
75.80 Percentage of CD marker cells
Standard Deviation 6.933
|
74.36 Percentage of CD marker cells
Standard Deviation 9.552
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
48.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
86.60 Percentage of CD marker cells
Standard Deviation 0.566
|
—
|
77.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; D8; n=1, 3, 0, 5, 4, 8
|
72.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
69.67 Percentage of CD marker cells
Standard Deviation 17.310
|
—
|
86.30 Percentage of CD marker cells
Standard Deviation 1.505
|
77.53 Percentage of CD marker cells
Standard Deviation 7.566
|
75.31 Percentage of CD marker cells
Standard Deviation 8.234
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; D15; S1; n=1, 3, 1, 5, 4, 9
|
73.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
68.97 Percentage of CD marker cells
Standard Deviation 19.410
|
36.8 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
87.52 Percentage of CD marker cells
Standard Deviation 1.359
|
76.08 Percentage of CD marker cells
Standard Deviation 8.844
|
76.50 Percentage of CD marker cells
Standard Deviation 5.723
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
48.9 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; D29; n=1, 3, 1, 4, 4, 8
|
76.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
69.97 Percentage of CD marker cells
Standard Deviation 17.609
|
36.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
87.30 Percentage of CD marker cells
Standard Deviation 1.753
|
73.58 Percentage of CD marker cells
Standard Deviation 9.783
|
74.49 Percentage of CD marker cells
Standard Deviation 12.798
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; FU; n=1, 2, 0, 3, 1, 4
|
64.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
77.15 Percentage of CD marker cells
Standard Deviation 7.425
|
—
|
83.53 Percentage of CD marker cells
Standard Deviation 7.966
|
42.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
70.13 Percentage of CD marker cells
Standard Deviation 11.425
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
58.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; D1; 1 h; n=1, 3, 1, 5, 4, 9
|
8.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.20 Percentage of CD marker cells
Standard Deviation 3.538
|
20.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
31.24 Percentage of CD marker cells
Standard Deviation 21.617
|
20.48 Percentage of CD marker cells
Standard Deviation 10.935
|
23.18 Percentage of CD marker cells
Standard Deviation 10.434
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; D1; 6 h; n=1, 3, 1, 5, 4, 11
|
8.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.47 Percentage of CD marker cells
Standard Deviation 2.548
|
23.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
30.82 Percentage of CD marker cells
Standard Deviation 22.379
|
23.38 Percentage of CD marker cells
Standard Deviation 11.738
|
22.86 Percentage of CD marker cells
Standard Deviation 11.701
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
21.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.70 Percentage of CD marker cells
Standard Deviation 7.071
|
—
|
40.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; D8; n=1, 3, 0, 5, 4, 8
|
10.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.70 Percentage of CD marker cells
Standard Deviation 4.987
|
—
|
35.24 Percentage of CD marker cells
Standard Deviation 22.320
|
24.60 Percentage of CD marker cells
Standard Deviation 12.511
|
23.76 Percentage of CD marker cells
Standard Deviation 9.382
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; D15; S1; n=1, 3, 1, 5, 4, 9
|
9.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.90 Percentage of CD marker cells
Standard Deviation 6.843
|
13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
36.46 Percentage of CD marker cells
Standard Deviation 22.405
|
26.25 Percentage of CD marker cells
Standard Deviation 13.843
|
27.00 Percentage of CD marker cells
Standard Deviation 11.668
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
15.7 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; D29; n=1, 3, 1, 4, 4, 8
|
11.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.93 Percentage of CD marker cells
Standard Deviation 6.110
|
17.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
40.85 Percentage of CD marker cells
Standard Deviation 23.034
|
23.05 Percentage of CD marker cells
Standard Deviation 11.997
|
20.40 Percentage of CD marker cells
Standard Deviation 13.234
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; FU; n=1, 2, 0, 3, 1, 4
|
7.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.55 Percentage of CD marker cells
Standard Deviation 4.455
|
—
|
45.10 Percentage of CD marker cells
Standard Deviation 29.487
|
6.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
31.88 Percentage of CD marker cells
Standard Deviation 4.661
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
21.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; D1; pre n=1, 3, 1, 5, 4, 9
|
50.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
45.90 Percentage of CD marker cells
Standard Deviation 9.124
|
36.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
50.76 Percentage of CD marker cells
Standard Deviation 20.204
|
45.58 Percentage of CD marker cells
Standard Deviation 4.365
|
47.71 Percentage of CD marker cells
Standard Deviation 14.059
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; D1; 1 h; n=1, 3, 1, 5, 4, 9
|
66.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.77 Percentage of CD marker cells
Standard Deviation 8.732
|
36.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
54.92 Percentage of CD marker cells
Standard Deviation 19.213
|
53.90 Percentage of CD marker cells
Standard Deviation 6.349
|
51.10 Percentage of CD marker cells
Standard Deviation 17.633
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; D1; 6 h; n=1, 3, 1, 5, 4, 11
|
72.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
54.10 Percentage of CD marker cells
Standard Deviation 13.421
|
36.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
55.26 Percentage of CD marker cells
Standard Deviation 19.752
|
53.28 Percentage of CD marker cells
Standard Deviation 10.943
|
49.26 Percentage of CD marker cells
Standard Deviation 17.654
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
26.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
66.35 Percentage of CD marker cells
Standard Deviation 7.425
|
—
|
36.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; D8; n=1, 3, 0, 5, 4, 8
|
63.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
46.80 Percentage of CD marker cells
Standard Deviation 12.759
|
—
|
50.48 Percentage of CD marker cells
Standard Deviation 21.133
|
51.70 Percentage of CD marker cells
Standard Deviation 11.040
|
51.48 Percentage of CD marker cells
Standard Deviation 8.065
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; D15; S1; n=1, 3, 1, 5, 4, 9
|
63.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
48.37 Percentage of CD marker cells
Standard Deviation 12.659
|
24.3 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
50.56 Percentage of CD marker cells
Standard Deviation 21.357
|
49.60 Percentage of CD marker cells
Standard Deviation 9.910
|
49.08 Percentage of CD marker cells
Standard Deviation 13.029
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
36.1 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; D29; n=1, 3, 1, 4, 4, 8
|
65.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
49.10 Percentage of CD marker cells
Standard Deviation 12.137
|
19.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
45.55 Percentage of CD marker cells
Standard Deviation 21.821
|
50.43 Percentage of CD marker cells
Standard Deviation 3.402
|
54.63 Percentage of CD marker cells
Standard Deviation 13.806
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; FU; n=1, 2, 0, 3, 1, 4
|
56.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.50 Percentage of CD marker cells
Standard Deviation 3.394
|
—
|
38.20 Percentage of CD marker cells
Standard Deviation 21.565
|
36.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
37.53 Percentage of CD marker cells
Standard Deviation 16.020
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD8-; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
38.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; D1; pre n=1, 3, 1, 5, 4, 9
|
24.3 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.50 Percentage of CD marker cells
Standard Deviation 7.375
|
25.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.96 Percentage of CD marker cells
Standard Deviation 1.757
|
13.83 Percentage of CD marker cells
Standard Deviation 12.467
|
10.63 Percentage of CD marker cells
Standard Deviation 8.253
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; D1; 1 h; n=1, 3, 1, 5, 4, 9
|
9.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.03 Percentage of CD marker cells
Standard Deviation 5.972
|
32.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.44 Percentage of CD marker cells
Standard Deviation 2.411
|
8.00 Percentage of CD marker cells
Standard Deviation 8.198
|
8.90 Percentage of CD marker cells
Standard Deviation 6.203
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; D1; 6 h; n=1, 3, 1, 5, 4, 11
|
3.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.80 Percentage of CD marker cells
Standard Deviation 6.538
|
23.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
3.30 Percentage of CD marker cells
Standard Deviation 2.314
|
6.43 Percentage of CD marker cells
Standard Deviation 4.407
|
7.44 Percentage of CD marker cells
Standard Deviation 4.569
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
35.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
2.50 Percentage of CD marker cells
Standard Deviation 0.566
|
—
|
4.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; D8; n=1, 3, 0, 5, 4, 8
|
11.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.71 Percentage of CD marker cells
Standard Deviation 12.293
|
—
|
5.62 Percentage of CD marker cells
Standard Deviation 3.128
|
9.23 Percentage of CD marker cells
Standard Deviation 5.762
|
11.23 Percentage of CD marker cells
Standard Deviation 7.852
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; D15; S1; n=1, 3, 1, 5, 4, 9
|
11.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.73 Percentage of CD marker cells
Standard Deviation 11.816
|
47.7 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.54 Percentage of CD marker cells
Standard Deviation 3.138
|
9.50 Percentage of CD marker cells
Standard Deviation 6.470
|
10.33 Percentage of CD marker cells
Standard Deviation 7.555
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
7.6 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; FU; n=1, 2, 0, 3, 1, 4
|
20.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.65 Percentage of CD marker cells
Standard Deviation 4.031
|
—
|
6.67 Percentage of CD marker cells
Standard Deviation 2.237
|
43.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.03 Percentage of CD marker cells
Standard Deviation 10.920
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
19.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; D1; pre; n=1, 3, 1, 5, 4, 9
|
25.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.03 Percentage of CD marker cells
Standard Deviation 5.636
|
25.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.88 Percentage of CD marker cells
Standard Deviation 1.221
|
15.93 Percentage of CD marker cells
Standard Deviation 11.588
|
12.16 Percentage of CD marker cells
Standard Deviation 7.479
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9
|
10.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.13 Percentage of CD marker cells
Standard Deviation 4.562
|
32.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.30 Percentage of CD marker cells
Standard Deviation 1.581
|
10.50 Percentage of CD marker cells
Standard Deviation 7.470
|
10.74 Percentage of CD marker cells
Standard Deviation 6.300
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11
|
4.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.47 Percentage of CD marker cells
Standard Deviation 5.934
|
26.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.70 Percentage of CD marker cells
Standard Deviation 1.913
|
9.43 Percentage of CD marker cells
Standard Deviation 3.079
|
10.71 Percentage of CD marker cells
Standard Deviation 7.319
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
42.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.10 Percentage of CD marker cells
Standard Deviation 0.141
|
—
|
5.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; D15; S1; n=1, 3, 1, 5, 4, 9
|
13.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.53 Percentage of CD marker cells
Standard Deviation 11.288
|
50.2 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.96 Percentage of CD marker cells
Standard Deviation 2.266
|
11.73 Percentage of CD marker cells
Standard Deviation 6.548
|
8.39 Percentage of CD marker cells
Standard Deviation 4.622
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
8.7 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; FU; n=1, 2, 0, 3, 1, 4
|
22.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.80 Percentage of CD marker cells
Standard Deviation 1.556
|
—
|
8.37 Percentage of CD marker cells
Standard Deviation 3.493
|
44.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.95 Percentage of CD marker cells
Standard Deviation 8.912
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
22.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9
|
3.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.17 Percentage of CD marker cells
Standard Deviation 8.905
|
2.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.18 Percentage of CD marker cells
Standard Deviation 10.303
|
6.20 Percentage of CD marker cells
Standard Deviation 4.774
|
4.67 Percentage of CD marker cells
Standard Deviation 2.707
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9
|
1.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.03 Percentage of CD marker cells
Standard Deviation 8.410
|
1.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.70 Percentage of CD marker cells
Standard Deviation 7.601
|
6.65 Percentage of CD marker cells
Standard Deviation 7.102
|
4.20 Percentage of CD marker cells
Standard Deviation 3.321
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11
|
1.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.87 Percentage of CD marker cells
Standard Deviation 7.566
|
13.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.50 Percentage of CD marker cells
Standard Deviation 11.924
|
8.50 Percentage of CD marker cells
Standard Deviation 10.745
|
4.17 Percentage of CD marker cells
Standard Deviation 3.299
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
3.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.90 Percentage of CD marker cells
Standard Deviation 14.001
|
—
|
7.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; D8; n=1, 3, 0, 5, 4, 8
|
3.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.23 Percentage of CD marker cells
Standard Deviation 8.977
|
—
|
12.36 Percentage of CD marker cells
Standard Deviation 8.813
|
5.83 Percentage of CD marker cells
Standard Deviation 2.756
|
3.49 Percentage of CD marker cells
Standard Deviation 2.801
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9
|
2.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.40 Percentage of CD marker cells
Standard Deviation 8.118
|
1.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.48 Percentage of CD marker cells
Standard Deviation 12.640
|
8.15 Percentage of CD marker cells
Standard Deviation 3.746
|
4.43 Percentage of CD marker cells
Standard Deviation 3.015
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
1.3 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; D29; n=1, 3, 1, 4, 4, 8
|
2.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.33 Percentage of CD marker cells
Standard Deviation 8.629
|
3.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.88 Percentage of CD marker cells
Standard Deviation 5.197
|
11.78 Percentage of CD marker cells
Standard Deviation 9.751
|
2.91 Percentage of CD marker cells
Standard Deviation 2.635
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; FU; n=1, 2, 0, 3, 1, 4
|
2.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.20 Percentage of CD marker cells
Standard Deviation 13.294
|
—
|
16.07 Percentage of CD marker cells
Standard Deviation 6.757
|
3.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.10 Percentage of CD marker cells
Standard Deviation 2.665
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3+CD56+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
1.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9
|
23.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.23 Percentage of CD marker cells
Standard Deviation 6.307
|
23.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.48 Percentage of CD marker cells
Standard Deviation 1.638
|
13.25 Percentage of CD marker cells
Standard Deviation 12.307
|
9.58 Percentage of CD marker cells
Standard Deviation 7.480
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; D1;1 h; n=1, 3, 1, 5, 4, 9
|
9.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.10 Percentage of CD marker cells
Standard Deviation 5.237
|
31.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
3.98 Percentage of CD marker cells
Standard Deviation 2.244
|
7.65 Percentage of CD marker cells
Standard Deviation 8.118
|
7.98 Percentage of CD marker cells
Standard Deviation 5.768
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; D1;6 h; n=1,3,1,5,4,11
|
3.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.90 Percentage of CD marker cells
Standard Deviation 5.403
|
19.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
2.92 Percentage of CD marker cells
Standard Deviation 2.348
|
6.10 Percentage of CD marker cells
Standard Deviation 4.221
|
6.22 Percentage of CD marker cells
Standard Deviation 4.445
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
33.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
2.40 Percentage of CD marker cells
Standard Deviation 0.566
|
—
|
4.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; D8; n=1, 3, 0, 5, 4, 8
|
10.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.33 Percentage of CD marker cells
Standard Deviation 10.979
|
—
|
5.00 Percentage of CD marker cells
Standard Deviation 2.891
|
8.68 Percentage of CD marker cells
Standard Deviation 5.465
|
8.96 Percentage of CD marker cells
Standard Deviation 6.217
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9
|
10.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.93 Percentage of CD marker cells
Standard Deviation 11.007
|
43.5 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.14 Percentage of CD marker cells
Standard Deviation 2.926
|
8.88 Percentage of CD marker cells
Standard Deviation 6.357
|
6.54 Percentage of CD marker cells
Standard Deviation 4.360
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243; D29; n=1,3,1,4,4,8
|
62.99 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
73.88 Percentage of CD marker cells
Standard Deviation 3.073
|
36.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
64.75 Percentage of CD marker cells
Standard Deviation 5.261
|
56.80 Percentage of CD marker cells
Standard Deviation 5.697
|
57.98 Percentage of CD marker cells
Standard Deviation 21.467
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
5.4 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; D29; n=1, 3, 1, 4, 4, 8
|
10.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.20 Percentage of CD marker cells
Standard Deviation 8.542
|
32.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.05 Percentage of CD marker cells
Standard Deviation 2.357
|
10.18 Percentage of CD marker cells
Standard Deviation 9.932
|
9.30 Percentage of CD marker cells
Standard Deviation 6.776
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; FU; n=1, 2, 0, 3, 1, 4
|
19.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.50 Percentage of CD marker cells
Standard Deviation 3.111
|
—
|
6.07 Percentage of CD marker cells
Standard Deviation 2.566
|
41.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
9.20 Percentage of CD marker cells
Standard Deviation 9.937
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD56+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
18.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; D1; pre n=1, 3, 1, 5, 4, 9
|
9.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.67 Percentage of CD marker cells
Standard Deviation 4.936
|
12.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.36 Percentage of CD marker cells
Standard Deviation 3.364
|
9.48 Percentage of CD marker cells
Standard Deviation 4.769
|
8.39 Percentage of CD marker cells
Standard Deviation 3.194
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; D1;1 h; n=1, 3, 1, 5, 4, 9
|
11.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.77 Percentage of CD marker cells
Standard Deviation 3.323
|
8.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.04 Percentage of CD marker cells
Standard Deviation 3.492
|
11.53 Percentage of CD marker cells
Standard Deviation 6.211
|
9.18 Percentage of CD marker cells
Standard Deviation 3.819
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; D1;6 h; n=1,3,1,5,4,11
|
11.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.23 Percentage of CD marker cells
Standard Deviation 3.329
|
6.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.36 Percentage of CD marker cells
Standard Deviation 3.817
|
10.83 Percentage of CD marker cells
Standard Deviation 6.636
|
9.00 Percentage of CD marker cells
Standard Deviation 4.988
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
6.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.10 Percentage of CD marker cells
Standard Deviation 0.141
|
—
|
10.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; D8; n=1, 3, 0, 5, 4, 8
|
10.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.77 Percentage of CD marker cells
Standard Deviation 4.701
|
—
|
5.76 Percentage of CD marker cells
Standard Deviation 3.895
|
9.63 Percentage of CD marker cells
Standard Deviation 4.786
|
7.65 Percentage of CD marker cells
Standard Deviation 4.176
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; D15; S1; n=1, 3, 1, 5, 4, 9
|
10.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.03 Percentage of CD marker cells
Standard Deviation 6.116
|
7.9 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.10 Percentage of CD marker cells
Standard Deviation 3.180
|
9.25 Percentage of CD marker cells
Standard Deviation 4.339
|
8.90 Percentage of CD marker cells
Standard Deviation 4.170
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
26.2 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; D29; n=1, 3, 1, 4, 4, 8
|
8.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.37 Percentage of CD marker cells
Standard Deviation 7.392
|
13.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.10 Percentage of CD marker cells
Standard Deviation 3.995
|
10.53 Percentage of CD marker cells
Standard Deviation 6.106
|
7.44 Percentage of CD marker cells
Standard Deviation 4.324
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; FU; n=1, 2, 0, 3, 1, 4
|
10.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.05 Percentage of CD marker cells
Standard Deviation 4.313
|
—
|
6.17 Percentage of CD marker cells
Standard Deviation 8.361
|
8.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.33 Percentage of CD marker cells
Standard Deviation 6.019
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD19+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
15.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; D1; pre; n=1, 3, 1, 5, 4, 9
|
5.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.87 Percentage of CD marker cells
Standard Deviation 0.971
|
10.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.58 Percentage of CD marker cells
Standard Deviation 1.293
|
7.15 Percentage of CD marker cells
Standard Deviation 2.029
|
4.87 Percentage of CD marker cells
Standard Deviation 1.406
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; D1;1 h; n=1, 3, 1, 5, 4, 9
|
1.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
3.63 Percentage of CD marker cells
Standard Deviation 2.103
|
11.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.20 Percentage of CD marker cells
Standard Deviation 1.461
|
4.68 Percentage of CD marker cells
Standard Deviation 2.926
|
3.52 Percentage of CD marker cells
Standard Deviation 1.713
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; D1;6 h; n=1,3,1,5,4,11
|
4.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.37 Percentage of CD marker cells
Standard Deviation 2.804
|
11.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.24 Percentage of CD marker cells
Standard Deviation 1.756
|
5.80 Percentage of CD marker cells
Standard Deviation 2.389
|
5.23 Percentage of CD marker cells
Standard Deviation 2.581
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
5.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.10 Percentage of CD marker cells
Standard Deviation 2.828
|
—
|
4.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; D8; n=1, 3, 0, 5, 4, 8
|
7.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.30 Percentage of CD marker cells
Standard Deviation 0.872
|
—
|
6.60 Percentage of CD marker cells
Standard Deviation 1.594
|
7.10 Percentage of CD marker cells
Standard Deviation 2.223
|
5.40 Percentage of CD marker cells
Standard Deviation 2.115
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; D15; S1; n=1, 3, 1, 5, 4, 9
|
4.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.60 Percentage of CD marker cells
Standard Deviation 1.652
|
5.9 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.66 Percentage of CD marker cells
Standard Deviation 1.108
|
6.93 Percentage of CD marker cells
Standard Deviation 1.823
|
5.47 Percentage of CD marker cells
Standard Deviation 3.061
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
18.9 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; D29; n=1, 3, 1, 4, 4, 8
|
5.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.93 Percentage of CD marker cells
Standard Deviation 0.231
|
7.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.53 Percentage of CD marker cells
Standard Deviation 1.162
|
6.68 Percentage of CD marker cells
Standard Deviation 2.241
|
4.61 Percentage of CD marker cells
Standard Deviation 1.108
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; FU; n=1, 2, 0, 3, 1, 4
|
7.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
5.50 Percentage of CD marker cells
Standard Deviation 1.273
|
—
|
8.03 Percentage of CD marker cells
Standard Deviation 0.862
|
2.70 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
4.98 Percentage of CD marker cells
Standard Deviation 1.692
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD14+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
8.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; D1; pre; n=1, 3, 1, 5, 4, 9
|
67.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.37 Percentage of CD marker cells
Standard Deviation 3.710
|
83.47 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.92 Percentage of CD marker cells
Standard Deviation 7.038
|
82.50 Percentage of CD marker cells
Standard Deviation 3.378
|
75.71 Percentage of CD marker cells
Standard Deviation 15.845
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; D1;1 h; n=1, 3, 1, 5, 4, 9
|
76.94 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
79.76 Percentage of CD marker cells
Standard Deviation 2.213
|
87.72 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
81.88 Percentage of CD marker cells
Standard Deviation 8.557
|
86.01 Percentage of CD marker cells
Standard Deviation 3.898
|
78.53 Percentage of CD marker cells
Standard Deviation 16.993
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; D1;6 h; n=1,3,1,5,4,11
|
77.72 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
76.99 Percentage of CD marker cells
Standard Deviation 12.536
|
90.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
84.25 Percentage of CD marker cells
Standard Deviation 5.802
|
84.57 Percentage of CD marker cells
Standard Deviation 4.448
|
79.79 Percentage of CD marker cells
Standard Deviation 12.178
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
91.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
89.03 Percentage of CD marker cells
Standard Deviation 3.776
|
—
|
88.05 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; D8; n=1, 3, 0, 5, 4, 8
|
77.29 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
75.83 Percentage of CD marker cells
Standard Deviation 5.870
|
—
|
81.34 Percentage of CD marker cells
Standard Deviation 10.373
|
79.91 Percentage of CD marker cells
Standard Deviation 2.014
|
70.93 Percentage of CD marker cells
Standard Deviation 21.532
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; D15;S1; n=1, 3, 1, 5, 4, 9
|
81.61 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
79.04 Percentage of CD marker cells
Standard Deviation 3.286
|
96.49 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.28 Percentage of CD marker cells
Standard Deviation 6.867
|
81.68 Percentage of CD marker cells
Standard Deviation 7.216
|
78.53 Percentage of CD marker cells
Standard Deviation 20.178
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
92.76 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; D29; n=1, 3, 1, 4, 4, 8
|
79.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
81.92 Percentage of CD marker cells
Standard Deviation 2.273
|
85.01 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.73 Percentage of CD marker cells
Standard Deviation 6.688
|
83.00 Percentage of CD marker cells
Standard Deviation 6.240
|
74.56 Percentage of CD marker cells
Standard Deviation 17.788
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; FU; n=1, 2, 0, 3, 1, 4
|
77.38 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
84.40 Percentage of CD marker cells
Standard Deviation 1.506
|
—
|
81.52 Percentage of CD marker cells
Standard Deviation 12.737
|
76.46 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.85 Percentage of CD marker cells
Standard Deviation 19.555
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
64.88 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; D1; pre; n=1, 3, 1, 5, 4, 9
|
7.06 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.40 Percentage of CD marker cells
Standard Deviation 5.851
|
18.18 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.27 Percentage of CD marker cells
Standard Deviation 13.221
|
23.96 Percentage of CD marker cells
Standard Deviation 12.309
|
25.04 Percentage of CD marker cells
Standard Deviation 30.481
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; D1;1 h; n=1, 3, 1, 5,4,9
|
12.19 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.18 Percentage of CD marker cells
Standard Deviation 8.160
|
8.77 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.43 Percentage of CD marker cells
Standard Deviation 13.416
|
24.66 Percentage of CD marker cells
Standard Deviation 13.827
|
23.16 Percentage of CD marker cells
Standard Deviation 24.866
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; D1;6 h; n=1,3,1,5,4,11
|
14.85 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.30 Percentage of CD marker cells
Standard Deviation 6.477
|
40.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
32.01 Percentage of CD marker cells
Standard Deviation 16.156
|
21.55 Percentage of CD marker cells
Standard Deviation 12.001
|
21.82 Percentage of CD marker cells
Standard Deviation 17.204
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; D2; n=0, 0, 1, 2, 0, 1
|
—
|
—
|
26.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
31.96 Percentage of CD marker cells
Standard Deviation 9.454
|
—
|
30.82 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; D8; n=1, 3, 0, 5, 4, 8
|
33.73 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.90 Percentage of CD marker cells
Standard Deviation 3.044
|
—
|
22.42 Percentage of CD marker cells
Standard Deviation 10.572
|
14.43 Percentage of CD marker cells
Standard Deviation 1.615
|
27.85 Percentage of CD marker cells
Standard Deviation 27.884
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; D15; S1; n=1, 3, 1, 5, 4, 9
|
17.29 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.72 Percentage of CD marker cells
Standard Deviation 4.937
|
38.6 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.00 Percentage of CD marker cells
Standard Deviation 8.663
|
18.30 Percentage of CD marker cells
Standard Deviation 3.558
|
21.68 Percentage of CD marker cells
Standard Deviation 15.816
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
65.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; D29; n=1, 3, 1, 4, 4, 8
|
16.94 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.78 Percentage of CD marker cells
Standard Deviation 3.719
|
52.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.08 Percentage of CD marker cells
Standard Deviation 4.869
|
27.70 Percentage of CD marker cells
Standard Deviation 12.686
|
17.22 Percentage of CD marker cells
Standard Deviation 6.799
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; FU; n=1, 2, 0, 3, 1, 4
|
14.38 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.49 Percentage of CD marker cells
Standard Deviation 13.902
|
—
|
31.28 Percentage of CD marker cells
Standard Deviation 29.410
|
11.64 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.42 Percentage of CD marker cells
Standard Deviation 15.633
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD107+; USC; n=0, 0, 1, 0, 0, 0
|
—
|
—
|
16.51 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+; D1; pre; n=1,3,1,5,4,9
|
6.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.33 Percentage of CD marker cells
Standard Deviation 5.869
|
18.18 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.05 Percentage of CD marker cells
Standard Deviation 12.990
|
23.53 Percentage of CD marker cells
Standard Deviation 11.967
|
24.68 Percentage of CD marker cells
Standard Deviation 30.659
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+; D1;1 h;n=1,3,1,5,4,9
|
11.81 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.86 Percentage of CD marker cells
Standard Deviation 7.795
|
8.77 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.29 Percentage of CD marker cells
Standard Deviation 13.208
|
24.42 Percentage of CD marker cells
Standard Deviation 13.709
|
22.85 Percentage of CD marker cells
Standard Deviation 24.965
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
|
14.85 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.29 Percentage of CD marker cells
Standard Deviation 6.364
|
38.16 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
31.96 Percentage of CD marker cells
Standard Deviation 16.199
|
21.33 Percentage of CD marker cells
Standard Deviation 11.655
|
21.34 Percentage of CD marker cells
Standard Deviation 17.411
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
26.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
31.42 Percentage of CD marker cells
Standard Deviation 10.218
|
—
|
30.19 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+; D8; n=1,3,0,5,4,8
|
32.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.77 Percentage of CD marker cells
Standard Deviation 3.013
|
—
|
22.35 Percentage of CD marker cells
Standard Deviation 10.534
|
14.40 Percentage of CD marker cells
Standard Deviation 1.591
|
27.19 Percentage of CD marker cells
Standard Deviation 27.949
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+; D15; S1;n=1,3,1,5,4,9
|
16.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.60 Percentage of CD marker cells
Standard Deviation 4.890
|
38.6 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.94 Percentage of CD marker cells
Standard Deviation 8.669
|
18.11 Percentage of CD marker cells
Standard Deviation 3.584
|
21.11 Percentage of CD marker cells
Standard Deviation 16.206
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+; D15; S2;n=0,0,1,0,0, 0
|
—
|
—
|
64.8 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+; D29; n=1,3,1,4,4,8
|
16.42 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.70 Percentage of CD marker cells
Standard Deviation 3.598
|
50.41 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.76 Percentage of CD marker cells
Standard Deviation 4.922
|
27.36 Percentage of CD marker cells
Standard Deviation 12.492
|
16.08 Percentage of CD marker cells
Standard Deviation 6.127
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+; FU; n=1,2,0,3,1,4
|
14.34 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.24 Percentage of CD marker cells
Standard Deviation 13.548
|
—
|
31.06 Percentage of CD marker cells
Standard Deviation 29.550
|
11.56 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.16 Percentage of CD marker cells
Standard Deviation 15.866
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107+; USC; n=0,0,1,0,0,0
|
—
|
—
|
15.77 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-; D1;pre; n=1,3,1,5,4,9
|
61.07 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
67.04 Percentage of CD marker cells
Standard Deviation 7.996
|
65.29 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
61.87 Percentage of CD marker cells
Standard Deviation 9.438
|
58.97 Percentage of CD marker cells
Standard Deviation 12.115
|
51.03 Percentage of CD marker cells
Standard Deviation 22.210
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-; D1;1 h;n=1,3,1,5,4,9
|
65.12 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
64.90 Percentage of CD marker cells
Standard Deviation 8.250
|
78.95 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
60.59 Percentage of CD marker cells
Standard Deviation 8.489
|
61.59 Percentage of CD marker cells
Standard Deviation 10.979
|
55.68 Percentage of CD marker cells
Standard Deviation 18.837
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
|
62.87 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
61.71 Percentage of CD marker cells
Standard Deviation 10.282
|
52.63 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.29 Percentage of CD marker cells
Standard Deviation 11.006
|
63.25 Percentage of CD marker cells
Standard Deviation 9.771
|
58.44 Percentage of CD marker cells
Standard Deviation 14.956
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
65.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
57.62 Percentage of CD marker cells
Standard Deviation 13.987
|
—
|
57.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-; D8; n=1,3,0,5,4,8
|
44.49 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
69.06 Percentage of CD marker cells
Standard Deviation 8.555
|
—
|
58.99 Percentage of CD marker cells
Standard Deviation 8.379
|
65.52 Percentage of CD marker cells
Standard Deviation 2.097
|
43.74 Percentage of CD marker cells
Standard Deviation 17.564
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-; D15;S1; n=1,3,1,5,4,9
|
64.68 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
71.45 Percentage of CD marker cells
Standard Deviation 1.611
|
57.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
63.34 Percentage of CD marker cells
Standard Deviation 4.338
|
63.57 Percentage of CD marker cells
Standard Deviation 6.498
|
57.42 Percentage of CD marker cells
Standard Deviation 15.273
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
27.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-; D29; n=1,3,1,4,4,8
|
62.87 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
73.22 Percentage of CD marker cells
Standard Deviation 4.103
|
34.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
61.98 Percentage of CD marker cells
Standard Deviation 6.511
|
55.64 Percentage of CD marker cells
Standard Deviation 6.702
|
58.48 Percentage of CD marker cells
Standard Deviation 19.691
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-; FU; n=1,2,0,3,1,4
|
63.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
62.16 Percentage of CD marker cells
Standard Deviation 15.047
|
—
|
50.46 Percentage of CD marker cells
Standard Deviation 18.585
|
64.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
53.69 Percentage of CD marker cells
Standard Deviation 9.671
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69+CD107-; USC; n=0,0,1,0,0,0
|
—
|
—
|
49.11 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+; D1;pre n=1,3,1,5,4,9
|
0.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.07 Percentage of CD marker cells
Standard Deviation 0.115
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.22 Percentage of CD marker cells
Standard Deviation 0.265
|
0.43 Percentage of CD marker cells
Standard Deviation 0.395
|
0.36 Percentage of CD marker cells
Standard Deviation 0.740
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+; D1;1 h;n=1,3,1,5,4,9
|
0.38 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.31 Percentage of CD marker cells
Standard Deviation 0.399
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.14 Percentage of CD marker cells
Standard Deviation 0.238
|
0.24 Percentage of CD marker cells
Standard Deviation 0.441
|
0.32 Percentage of CD marker cells
Standard Deviation 0.494
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.09 Percentage of CD marker cells
Standard Deviation 0.162
|
2.63 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.05 Percentage of CD marker cells
Standard Deviation 0.069
|
0.23 Percentage of CD marker cells
Standard Deviation 0.403
|
0.48 Percentage of CD marker cells
Standard Deviation 1.014
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.54 Percentage of CD marker cells
Standard Deviation 0.764
|
—
|
0.63 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+; D8; n=1,3,0,5,4,8
|
0.94 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.14 Percentage of CD marker cells
Standard Deviation 0.029
|
—
|
0.07 Percentage of CD marker cells
Standard Deviation 0.100
|
0.04 Percentage of CD marker cells
Standard Deviation 0.041
|
0.66 Percentage of CD marker cells
Standard Deviation 0.524
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+; D15;S1; n=1,3,1,5,4,9
|
0.37 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.12 Percentage of CD marker cells
Standard Deviation 0.102
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.05 Percentage of CD marker cells
Standard Deviation 0.121
|
0.19 Percentage of CD marker cells
Standard Deviation 0.236
|
0.56 Percentage of CD marker cells
Standard Deviation 0.890
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
1.09 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+; D29; n=1,3,1,4,4,8
|
0.52 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.07 Percentage of CD marker cells
Standard Deviation 0.127
|
2.45 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.32 Percentage of CD marker cells
Standard Deviation 0.326
|
0.34 Percentage of CD marker cells
Standard Deviation 0.241
|
1.14 Percentage of CD marker cells
Standard Deviation 1.844
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+; FU; n=1,2,0,3,1,4
|
0.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.26 Percentage of CD marker cells
Standard Deviation 0.361
|
—
|
0.22 Percentage of CD marker cells
Standard Deviation 0.333
|
0.09 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.27 Percentage of CD marker cells
Standard Deviation 0.324
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107+; USC; n=0,0,1,0,0,0
|
—
|
—
|
0.74 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-; D1;pre; n=1,3,1,5,4,9
|
31.87 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.57 Percentage of CD marker cells
Standard Deviation 3.611
|
16.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.86 Percentage of CD marker cells
Standard Deviation 7.256
|
17.07 Percentage of CD marker cells
Standard Deviation 3.528
|
23.98 Percentage of CD marker cells
Standard Deviation 15.442
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-; D1;1 h;n=1,3,1,5,4,9
|
22.68 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.93 Percentage of CD marker cells
Standard Deviation 2.396
|
12.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.98 Percentage of CD marker cells
Standard Deviation 8.736
|
13.75 Percentage of CD marker cells
Standard Deviation 3.880
|
21.36 Percentage of CD marker cells
Standard Deviation 16.671
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
|
22.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.91 Percentage of CD marker cells
Standard Deviation 12.511
|
6.58 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.70 Percentage of CD marker cells
Standard Deviation 5.783
|
15.21 Percentage of CD marker cells
Standard Deviation 4.603
|
19.98 Percentage of CD marker cells
Standard Deviation 11.842
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
9.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.43 Percentage of CD marker cells
Standard Deviation 4.540
|
—
|
11.32 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-; D8; n=1,3,0,5,4,8
|
21.78 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.03 Percentage of CD marker cells
Standard Deviation 5.842
|
—
|
18.63 Percentage of CD marker cells
Standard Deviation 10.331
|
20.05 Percentage of CD marker cells
Standard Deviation 2.014
|
28.47 Percentage of CD marker cells
Standard Deviation 21.443
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-; D15; S1;n=1,3,1,5,4,9
|
18.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.84 Percentage of CD marker cells
Standard Deviation 3.338
|
3.51 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.67 Percentage of CD marker cells
Standard Deviation 6.810
|
18.13 Percentage of CD marker cells
Standard Deviation 7.060
|
20.92 Percentage of CD marker cells
Standard Deviation 19.349
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
6.15 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-; D29; n=1,3,1,4,4,8
|
20.20 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.00 Percentage of CD marker cells
Standard Deviation 2.247
|
12.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.97 Percentage of CD marker cells
Standard Deviation 6.747
|
16.67 Percentage of CD marker cells
Standard Deviation 6.466
|
24.35 Percentage of CD marker cells
Standard Deviation 16.239
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-; FU; n=1,2,0,3,1,4
|
22.59 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.35 Percentage of CD marker cells
Standard Deviation 1.146
|
—
|
18.34 Percentage of CD marker cells
Standard Deviation 12.586
|
23.54 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.89 Percentage of CD marker cells
Standard Deviation 19.247
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD16+CD69-CD107-; USC; n=0,0,1,0,0,0
|
—
|
—
|
34.38 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+; D1;pre; n=1,3,1,5,4,9
|
67.22 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
78.33 Percentage of CD marker cells
Standard Deviation 3.952
|
82.26 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
77.55 Percentage of CD marker cells
Standard Deviation 7.943
|
77.94 Percentage of CD marker cells
Standard Deviation 6.341
|
71.81 Percentage of CD marker cells
Standard Deviation 14.980
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+; D1;1 h;n=1,3,1,5,4,9
|
75.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
77.13 Percentage of CD marker cells
Standard Deviation 4.906
|
86.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
79.21 Percentage of CD marker cells
Standard Deviation 8.936
|
80.38 Percentage of CD marker cells
Standard Deviation 5.074
|
73.55 Percentage of CD marker cells
Standard Deviation 18.249
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+;D1;6 h;n=1,3,1,5,4,11
|
79.56 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
74.82 Percentage of CD marker cells
Standard Deviation 11.935
|
92.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.05 Percentage of CD marker cells
Standard Deviation 5.668
|
79.33 Percentage of CD marker cells
Standard Deviation 8.307
|
74.28 Percentage of CD marker cells
Standard Deviation 14.068
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+; D2; n=0,0,1,2,0,1
|
—
|
—
|
87.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
84.69 Percentage of CD marker cells
Standard Deviation 5.862
|
—
|
84.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+; D8; n=1,3,0,5,4,8
|
75.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
72.08 Percentage of CD marker cells
Standard Deviation 3.948
|
—
|
77.49 Percentage of CD marker cells
Standard Deviation 9.757
|
75.71 Percentage of CD marker cells
Standard Deviation 6.039
|
64.20 Percentage of CD marker cells
Standard Deviation 17.380
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+; D15;S1; n=1,3,1,5,4,9
|
80.07 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
76.83 Percentage of CD marker cells
Standard Deviation 2.746
|
93.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
76.69 Percentage of CD marker cells
Standard Deviation 5.772
|
77.05 Percentage of CD marker cells
Standard Deviation 1.250
|
74.14 Percentage of CD marker cells
Standard Deviation 18.976
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
90.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+; D29; n=1,3,1,4,4,8
|
76.99 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.41 Percentage of CD marker cells
Standard Deviation 3.445
|
83.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
77.90 Percentage of CD marker cells
Standard Deviation 5.693
|
78.39 Percentage of CD marker cells
Standard Deviation 3.376
|
72.21 Percentage of CD marker cells
Standard Deviation 20.172
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+; FU; n=1,2,0,3,1,4
|
75.72 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
83.15 Percentage of CD marker cells
Standard Deviation 0.643
|
—
|
78.85 Percentage of CD marker cells
Standard Deviation 8.804
|
76.62 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
75.78 Percentage of CD marker cells
Standard Deviation 15.172
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+; USC; n=0,0,1,0,0,0
|
—
|
—
|
64.59 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+; D1; pre; n=1,3,1,5,4,9
|
2.47 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.70 Percentage of CD marker cells
Standard Deviation 5.812
|
15.32 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.30 Percentage of CD marker cells
Standard Deviation 12.987
|
20.36 Percentage of CD marker cells
Standard Deviation 10.285
|
15.35 Percentage of CD marker cells
Standard Deviation 12.755
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+; D1;1 h;n=1,3,1,5,4,9
|
5.13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
13.87 Percentage of CD marker cells
Standard Deviation 7.853
|
6.69 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.11 Percentage of CD marker cells
Standard Deviation 11.990
|
18.36 Percentage of CD marker cells
Standard Deviation 8.295
|
13.92 Percentage of CD marker cells
Standard Deviation 14.620
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+;D1;6 h;n=1,3,1,5,4,11
|
14.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.66 Percentage of CD marker cells
Standard Deviation 7.368
|
31.76 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.41 Percentage of CD marker cells
Standard Deviation 13.644
|
19.50 Percentage of CD marker cells
Standard Deviation 10.930
|
17.82 Percentage of CD marker cells
Standard Deviation 13.218
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
21.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
28.04 Percentage of CD marker cells
Standard Deviation 7.347
|
—
|
26.27 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+; D8; n=1,3,0,5,4,8
|
32.45 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.79 Percentage of CD marker cells
Standard Deviation 2.953
|
—
|
17.46 Percentage of CD marker cells
Standard Deviation 7.730
|
12.81 Percentage of CD marker cells
Standard Deviation 2.027
|
15.17 Percentage of CD marker cells
Standard Deviation 12.783
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+; D15;S1; n=1,3,1,5,4,9
|
15.54 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.48 Percentage of CD marker cells
Standard Deviation 3.558
|
39.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.18 Percentage of CD marker cells
Standard Deviation 7.919
|
13.95 Percentage of CD marker cells
Standard Deviation 4.221
|
16.02 Percentage of CD marker cells
Standard Deviation 10.352
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
54.4 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+; FU; n=1,2,0,3,1,4
|
13.08 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.93 Percentage of CD marker cells
Standard Deviation 11.469
|
—
|
26.54 Percentage of CD marker cells
Standard Deviation 22.053
|
11.46 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.63 Percentage of CD marker cells
Standard Deviation 17.232
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD107+; USC; n=0,0,1,0,0,0
|
—
|
—
|
16.45 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+; D1; pre n=1,3,1,5,4,9
|
2.45 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
11.58 Percentage of CD marker cells
Standard Deviation 5.907
|
15.32 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.98 Percentage of CD marker cells
Standard Deviation 12.746
|
19.90 Percentage of CD marker cells
Standard Deviation 9.878
|
15.06 Percentage of CD marker cells
Standard Deviation 12.804
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
|
14.60 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.94 Percentage of CD marker cells
Standard Deviation 6.586
|
31.76 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.27 Percentage of CD marker cells
Standard Deviation 13.781
|
19.15 Percentage of CD marker cells
Standard Deviation 10.796
|
15.67 Percentage of CD marker cells
Standard Deviation 9.351
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
21.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.36 Percentage of CD marker cells
Standard Deviation 7.460
|
—
|
25.81 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+; D8; n=1,3,0,5,4,8
|
31.18 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.63 Percentage of CD marker cells
Standard Deviation 2.770
|
—
|
17.32 Percentage of CD marker cells
Standard Deviation 7.645
|
12.69 Percentage of CD marker cells
Standard Deviation 2.047
|
14.33 Percentage of CD marker cells
Standard Deviation 12.481
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+; D15;S1; n=1,3,1,5,4,9
|
15.13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.40 Percentage of CD marker cells
Standard Deviation 3.545
|
39.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.03 Percentage of CD marker cells
Standard Deviation 7.922
|
13.80 Percentage of CD marker cells
Standard Deviation 4.123
|
15.58 Percentage of CD marker cells
Standard Deviation 10.540
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
54.27 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+; D29; n=1,3,1,4,4,8
|
15.34 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
7.77 Percentage of CD marker cells
Standard Deviation 3.841
|
46.54 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.70 Percentage of CD marker cells
Standard Deviation 1.922
|
22.55 Percentage of CD marker cells
Standard Deviation 7.441
|
15.59 Percentage of CD marker cells
Standard Deviation 4.963
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+; FU; n=1,2,0,3,1,4
|
13.01 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.60 Percentage of CD marker cells
Standard Deviation 11.130
|
—
|
26.27 Percentage of CD marker cells
Standard Deviation 22.189
|
11.38 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.00 Percentage of CD marker cells
Standard Deviation 16.629
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107+; USC; n=0,0,1,0,0,0
|
—
|
—
|
15.52 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-; D1; pre; n=1,3,1,5,4,9
|
64.78 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
66.74 Percentage of CD marker cells
Standard Deviation 7.360
|
66.94 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
61.56 Percentage of CD marker cells
Standard Deviation 9.286
|
58.04 Percentage of CD marker cells
Standard Deviation 12.938
|
56.75 Percentage of CD marker cells
Standard Deviation 10.180
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-; D1;1 h;n=1,3,1,5,4,9
|
70.36 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
63.58 Percentage of CD marker cells
Standard Deviation 7.453
|
80.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
62.31 Percentage of CD marker cells
Standard Deviation 7.582
|
62.66 Percentage of CD marker cells
Standard Deviation 8.744
|
59.95 Percentage of CD marker cells
Standard Deviation 15.044
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
|
64.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
58.88 Percentage of CD marker cells
Standard Deviation 10.865
|
61.18 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
56.78 Percentage of CD marker cells
Standard Deviation 8.650
|
60.18 Percentage of CD marker cells
Standard Deviation 9.203
|
58.62 Percentage of CD marker cells
Standard Deviation 14.204
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
65.83 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
57.33 Percentage of CD marker cells
Standard Deviation 13.329
|
—
|
58.99 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-; D15;S1; n=1,3,1,5,4,9
|
64.95 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
70.43 Percentage of CD marker cells
Standard Deviation 0.830
|
54.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
62.66 Percentage of CD marker cells
Standard Deviation 4.313
|
63.25 Percentage of CD marker cells
Standard Deviation 5.044
|
58.55 Percentage of CD marker cells
Standard Deviation 14.595
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
36.52 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-; D8; n=1,3,0,5,4,8
|
44.15 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
65.44 Percentage of CD marker cells
Standard Deviation 6.176
|
—
|
60.18 Percentage of CD marker cells
Standard Deviation 8.140
|
63.02 Percentage of CD marker cells
Standard Deviation 5.005
|
49.87 Percentage of CD marker cells
Standard Deviation 13.422
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-; D29; n=1,3,1,4,4,8
|
61.65 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
72.64 Percentage of CD marker cells
Standard Deviation 2.420
|
36.99 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
63.21 Percentage of CD marker cells
Standard Deviation 4.900
|
55.84 Percentage of CD marker cells
Standard Deviation 6.851
|
56.62 Percentage of CD marker cells
Standard Deviation 21.533
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-; FU; n=1,2,0,3,1,4
|
62.71 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
63.55 Percentage of CD marker cells
Standard Deviation 11.780
|
—
|
52.58 Percentage of CD marker cells
Standard Deviation 16.165
|
65.24 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
52.78 Percentage of CD marker cells
Standard Deviation 12.864
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69+CD107-; USC; n=0,0,1,0,0,0
|
—
|
—
|
49.07 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+; D1; pre; n=1,3,1,5,4,9
|
0.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.11 Percentage of CD marker cells
Standard Deviation 0.095
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.31 Percentage of CD marker cells
Standard Deviation 0.267
|
0.46 Percentage of CD marker cells
Standard Deviation 0.425
|
0.29 Percentage of CD marker cells
Standard Deviation 0.558
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+; D1;1 h;n=1,3,1,5,4,9
|
0.17 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.31 Percentage of CD marker cells
Standard Deviation 0.412
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.21 Percentage of CD marker cells
Standard Deviation 0.123
|
0.64 Percentage of CD marker cells
Standard Deviation 0.660
|
0.32 Percentage of CD marker cells
Standard Deviation 0.364
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.72 Percentage of CD marker cells
Standard Deviation 0.968
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.14 Percentage of CD marker cells
Standard Deviation 0.226
|
0.35 Percentage of CD marker cells
Standard Deviation 0.262
|
2.15 Percentage of CD marker cells
Standard Deviation 5.749
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+; D2; n=0,0,1,2,0,1
|
—
|
—
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.68 Percentage of CD marker cells
Standard Deviation 0.113
|
—
|
0.46 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+; D8; n=1,3,0,5,4,8
|
1.27 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.16 Percentage of CD marker cells
Standard Deviation 0.182
|
—
|
0.14 Percentage of CD marker cells
Standard Deviation 0.186
|
0.11 Percentage of CD marker cells
Standard Deviation 0.109
|
0.84 Percentage of CD marker cells
Standard Deviation 1.031
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+; D15;S1; n=1,3,1,5,4,9
|
0.41 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.09 Percentage of CD marker cells
Standard Deviation 0.076
|
0 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.15 Percentage of CD marker cells
Standard Deviation 0.145
|
0.15 Percentage of CD marker cells
Standard Deviation 0.174
|
0.44 Percentage of CD marker cells
Standard Deviation 0.638
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
0.14 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+; D29; n=1,3,1,4,4,8
|
0.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.00 Percentage of CD marker cells
Standard Deviation 0.000
|
1.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.39 Percentage of CD marker cells
Standard Deviation 0.541
|
0.35 Percentage of CD marker cells
Standard Deviation 0.145
|
1.54 Percentage of CD marker cells
Standard Deviation 2.079
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+; FU; n=1,2,0,3,1,4
|
0.07 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.34 Percentage of CD marker cells
Standard Deviation 0.332
|
—
|
0.27 Percentage of CD marker cells
Standard Deviation 0.379
|
0.08 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.62 Percentage of CD marker cells
Standard Deviation 0.678
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107+; USC; n=0,0,1,0,0,0
|
—
|
—
|
0.93 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-; D1; pre; n=1,3,1,5,4,9
|
32.75 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.56 Percentage of CD marker cells
Standard Deviation 3.938
|
17.74 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.14 Percentage of CD marker cells
Standard Deviation 8.116
|
21.60 Percentage of CD marker cells
Standard Deviation 6.379
|
27.91 Percentage of CD marker cells
Standard Deviation 14.759
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-; D1;1 h;n=1,3,1,5,4,9
|
24.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
22.55 Percentage of CD marker cells
Standard Deviation 5.154
|
13.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.58 Percentage of CD marker cells
Standard Deviation 8.921
|
18.99 Percentage of CD marker cells
Standard Deviation 4.842
|
26.13 Percentage of CD marker cells
Standard Deviation 18.140
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
|
20.44 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.46 Percentage of CD marker cells
Standard Deviation 11.748
|
7.06 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.81 Percentage of CD marker cells
Standard Deviation 5.486
|
20.36 Percentage of CD marker cells
Standard Deviation 8.302
|
23.56 Percentage of CD marker cells
Standard Deviation 13.128
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-; D2; n=0,0,1,2,0,1
|
—
|
—
|
12.50 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.64 Percentage of CD marker cells
Standard Deviation 5.975
|
—
|
14.75 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-; D8; n=1,3,0,5,4,8
|
23.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.76 Percentage of CD marker cells
Standard Deviation 3.835
|
—
|
22.37 Percentage of CD marker cells
Standard Deviation 9.797
|
24.18 Percentage of CD marker cells
Standard Deviation 5.949
|
34.96 Percentage of CD marker cells
Standard Deviation 16.868
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-; D15;S1; n=1,3,1,5,4,9
|
19.57 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.09 Percentage of CD marker cells
Standard Deviation 2.774
|
6.67 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.16 Percentage of CD marker cells
Standard Deviation 5.735
|
22.81 Percentage of CD marker cells
Standard Deviation 1.095
|
25.43 Percentage of CD marker cells
Standard Deviation 18.427
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
9.08 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-; D29; n=1,3,1,4,4,8
|
22.56 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.59 Percentage of CD marker cells
Standard Deviation 3.445
|
14.80 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
21.73 Percentage of CD marker cells
Standard Deviation 5.751
|
21.27 Percentage of CD marker cells
Standard Deviation 3.470
|
26.26 Percentage of CD marker cells
Standard Deviation 18.208
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-; FU; n=1,2,0,3,1,4
|
24.28 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.52 Percentage of CD marker cells
Standard Deviation 0.311
|
—
|
20.87 Percentage of CD marker cells
Standard Deviation 8.475
|
23.30 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.60 Percentage of CD marker cells
Standard Deviation 15.370
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD69-CD107-; USC; n=0,0,1,0,0,0
|
—
|
—
|
34.48 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+; D1; pre; n=1,3,1,5,4,9
|
67.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
79.63 Percentage of CD marker cells
Standard Deviation 3.253
|
83.93 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.66 Percentage of CD marker cells
Standard Deviation 7.578
|
82.35 Percentage of CD marker cells
Standard Deviation 3.605
|
75.53 Percentage of CD marker cells
Standard Deviation 16.495
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+; D1;1 h;n=1,3,1,5,4,9
|
76.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
79.33 Percentage of CD marker cells
Standard Deviation 2.688
|
88.07 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
81.64 Percentage of CD marker cells
Standard Deviation 9.116
|
85.57 Percentage of CD marker cells
Standard Deviation 3.640
|
77.45 Percentage of CD marker cells
Standard Deviation 18.036
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+;D1;6 h;n=1,3,1,5,4,11
|
78.24 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
76.67 Percentage of CD marker cells
Standard Deviation 11.942
|
93.65 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
83.35 Percentage of CD marker cells
Standard Deviation 5.763
|
83.95 Percentage of CD marker cells
Standard Deviation 4.687
|
78.92 Percentage of CD marker cells
Standard Deviation 13.044
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+; D2; n=0,0,1,2,0,1
|
—
|
—
|
90.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
89.13 Percentage of CD marker cells
Standard Deviation 3.147
|
—
|
87.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+; D8; n=1,3,0,5,4,8
|
77.01 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
75.37 Percentage of CD marker cells
Standard Deviation 5.656
|
—
|
80.55 Percentage of CD marker cells
Standard Deviation 10.272
|
79.75 Percentage of CD marker cells
Standard Deviation 2.003
|
70.62 Percentage of CD marker cells
Standard Deviation 21.607
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+; D15;S1; n=1,3,1,5,4,9
|
81.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
78.47 Percentage of CD marker cells
Standard Deviation 3.127
|
97.12 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
79.94 Percentage of CD marker cells
Standard Deviation 6.952
|
80.67 Percentage of CD marker cells
Standard Deviation 5.845
|
79.09 Percentage of CD marker cells
Standard Deviation 19.651
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
94.42 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+; D29; n=1,3,1,4,4,8
|
78.98 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
81.90 Percentage of CD marker cells
Standard Deviation 2.566
|
85.89 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.16 Percentage of CD marker cells
Standard Deviation 7.448
|
82.36 Percentage of CD marker cells
Standard Deviation 4.976
|
74.62 Percentage of CD marker cells
Standard Deviation 18.799
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+; FU; n=1,2,0,3,1,4
|
77.43 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
83.80 Percentage of CD marker cells
Standard Deviation 1.485
|
—
|
81.09 Percentage of CD marker cells
Standard Deviation 12.356
|
76.73 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
80.93 Percentage of CD marker cells
Standard Deviation 19.159
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD69+; USC; n=0,0,1,0,0,0
|
—
|
—
|
65.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+; D1;pre; n=1,3,1,5,4,9
|
6.82 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.17 Percentage of CD marker cells
Standard Deviation 5.660
|
16.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.55 Percentage of CD marker cells
Standard Deviation 13.586
|
22.71 Percentage of CD marker cells
Standard Deviation 12.190
|
23.18 Percentage of CD marker cells
Standard Deviation 31.567
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+; D1;1 h;n=1,3,1,5,4,9
|
12.40 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.37 Percentage of CD marker cells
Standard Deviation 7.788
|
7.34 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.24 Percentage of CD marker cells
Standard Deviation 13.929
|
23.33 Percentage of CD marker cells
Standard Deviation 14.182
|
20.40 Percentage of CD marker cells
Standard Deviation 26.478
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+;D1;6 h;n=1,3,1,5,4,11
|
15.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.86 Percentage of CD marker cells
Standard Deviation 7.082
|
31.75 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.52 Percentage of CD marker cells
Standard Deviation 16.167
|
20.47 Percentage of CD marker cells
Standard Deviation 12.384
|
19.35 Percentage of CD marker cells
Standard Deviation 17.934
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+; D8; n=1,3,0,5,4,8
|
33.08 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.53 Percentage of CD marker cells
Standard Deviation 3.339
|
—
|
18.59 Percentage of CD marker cells
Standard Deviation 9.084
|
13.90 Percentage of CD marker cells
Standard Deviation 2.089
|
26.69 Percentage of CD marker cells
Standard Deviation 33.377
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+; D15;S1; n=1,3,1,5,4,9
|
16.23 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.20 Percentage of CD marker cells
Standard Deviation 4.025
|
40.38 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.69 Percentage of CD marker cells
Standard Deviation 8.825
|
14.72 Percentage of CD marker cells
Standard Deviation 4.613
|
21.04 Percentage of CD marker cells
Standard Deviation 17.138
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+; D15; S2; n=0,0,1,0,0,0
|
—
|
—
|
60.94 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+; D29; n=1,3,1,4,4,8
|
16.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.01 Percentage of CD marker cells
Standard Deviation 4.316
|
50.92 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.68 Percentage of CD marker cells
Standard Deviation 2.613
|
25.75 Percentage of CD marker cells
Standard Deviation 9.873
|
18.09 Percentage of CD marker cells
Standard Deviation 7.210
|
|
Percentage of Cluster of Differentiation (CD) Marker
CD45+CD3-CD56+CD16+CD107+; USC; n=0,0,1,0,0,0
|
—
|
—
|
16.42 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; D1;pre; n=1,3,1,5,4,9
|
6.63 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
12.09 Percentage of CD marker cells
Standard Deviation 5.664
|
16.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
17.32 Percentage of CD marker cells
Standard Deviation 13.319
|
22.27 Percentage of CD marker cells
Standard Deviation 11.808
|
22.97 Percentage of CD marker cells
Standard Deviation 31.676
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; D1;1h;n=1,3,1,5,4,9
|
12.01 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.02 Percentage of CD marker cells
Standard Deviation 7.382
|
7.34 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.15 Percentage of CD marker cells
Standard Deviation 13.818
|
23.12 Percentage of CD marker cells
Standard Deviation 14.060
|
20.23 Percentage of CD marker cells
Standard Deviation 26.492
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; D1;6h;n=1,3,1,5,4,11
|
15.03 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.75 Percentage of CD marker cells
Standard Deviation 6.934
|
31.75 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
27.46 Percentage of CD marker cells
Standard Deviation 16.219
|
20.23 Percentage of CD marker cells
Standard Deviation 12.033
|
19.06 Percentage of CD marker cells
Standard Deviation 18.044
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; D2; n=0,0,1,2,0,1
|
—
|
—
|
25.26 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
31.68 Percentage of CD marker cells
Standard Deviation 10.769
|
—
|
29.94 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; D8; n=1,3,0,5,4,8
|
32.10 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.47 Percentage of CD marker cells
Standard Deviation 3.238
|
—
|
18.50 Percentage of CD marker cells
Standard Deviation 9.029
|
13.88 Percentage of CD marker cells
Standard Deviation 2.075
|
26.20 Percentage of CD marker cells
Standard Deviation 33.362
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; D15;S1;n=1,3,1,5,4,9
|
15.97 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
6.13 Percentage of CD marker cells
Standard Deviation 3.908
|
40.38 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
14.62 Percentage of CD marker cells
Standard Deviation 8.827
|
14.55 Percentage of CD marker cells
Standard Deviation 4.521
|
20.62 Percentage of CD marker cells
Standard Deviation 17.353
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
60.94 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; D29; n=1,3,1,4,4,8
|
15.99 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
8.01 Percentage of CD marker cells
Standard Deviation 4.316
|
49.39 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
15.40 Percentage of CD marker cells
Standard Deviation 2.640
|
25.56 Percentage of CD marker cells
Standard Deviation 9.917
|
16.64 Percentage of CD marker cells
Standard Deviation 6.597
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; FU; n=1,2,0,3,1,4
|
13.66 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.29 Percentage of CD marker cells
Standard Deviation 13.668
|
—
|
29.58 Percentage of CD marker cells
Standard Deviation 28.512
|
11.59 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
25.41 Percentage of CD marker cells
Standard Deviation 14.820
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX241; USC; n=0,0,1,0,0,0
|
—
|
—
|
15.64 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243; D1; pre; n=1,3,1,5,4,9
|
61.33 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
67.54 Percentage of CD marker cells
Standard Deviation 8.092
|
66.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
63.34 Percentage of CD marker cells
Standard Deviation 9.199
|
60.08 Percentage of CD marker cells
Standard Deviation 11.697
|
52.56 Percentage of CD marker cells
Standard Deviation 22.645
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243; D1;1h; n=1,3,1,5,4,9
|
64.84 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
65.31 Percentage of CD marker cells
Standard Deviation 7.929
|
80.73 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
62.49 Percentage of CD marker cells
Standard Deviation 8.086
|
62.45 Percentage of CD marker cells
Standard Deviation 11.395
|
57.22 Percentage of CD marker cells
Standard Deviation 19.058
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243;D1;6h; n=1,3,1,5,4,11
|
63.21 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
61.93 Percentage of CD marker cells
Standard Deviation 9.710
|
61.90 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
55.89 Percentage of CD marker cells
Standard Deviation 11.139
|
63.72 Percentage of CD marker cells
Standard Deviation 9.993
|
59.86 Percentage of CD marker cells
Standard Deviation 14.378
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243; D2; n=0,0,1,2,0,1
|
—
|
—
|
65.26 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
57.46 Percentage of CD marker cells
Standard Deviation 13.909
|
—
|
57.96 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243; D15;S1; n=1,3,1,5,4,9
|
65.55 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
72.34 Percentage of CD marker cells
Standard Deviation 0.958
|
56.73 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
65.32 Percentage of CD marker cells
Standard Deviation 4.554
|
66.13 Percentage of CD marker cells
Standard Deviation 9.524
|
58.47 Percentage of CD marker cells
Standard Deviation 16.070
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243; D15;S2; n=0,0,1,0,0,0
|
—
|
—
|
33.48 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243; FU;n=1,2,0,3,1,4
|
63.77 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
64.51 Percentage of CD marker cells
Standard Deviation 15.146
|
—
|
51.52 Percentage of CD marker cells
Standard Deviation 18.071
|
65.13 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
55.52 Percentage of CD marker cells
Standard Deviation 9.421
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX243; USC;n=0,0,1,0,0,0
|
—
|
—
|
49.72 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; D1; pre; n=1,3,1,5,4,9
|
0.18 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.08 Percentage of CD marker cells
Standard Deviation 0.139
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.23 Percentage of CD marker cells
Standard Deviation 0.289
|
0.45 Percentage of CD marker cells
Standard Deviation 0.422
|
0.21 Percentage of CD marker cells
Standard Deviation 0.505
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; D1;1h;n=1,3,1,5,4,9
|
0.39 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.35 Percentage of CD marker cells
Standard Deviation 0.454
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.09 Percentage of CD marker cells
Standard Deviation 0.137
|
0.22 Percentage of CD marker cells
Standard Deviation 0.391
|
0.17 Percentage of CD marker cells
Standard Deviation 0.319
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; D1;6h;n=1,3,1,5,4,11
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.11 Percentage of CD marker cells
Standard Deviation 0.191
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.06 Percentage of CD marker cells
Standard Deviation 0.089
|
0.24 Percentage of CD marker cells
Standard Deviation 0.423
|
0.30 Percentage of CD marker cells
Standard Deviation 0.682
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; D2; n=0,0,1,2,0,1
|
—
|
—
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.57 Percentage of CD marker cells
Standard Deviation 0.799
|
—
|
0.64 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; D8; n=1,3,0,5,4,8
|
0.98 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.06 Percentage of CD marker cells
Standard Deviation 0.110
|
—
|
0.08 Percentage of CD marker cells
Standard Deviation 0.116
|
0.02 Percentage of CD marker cells
Standard Deviation 0.045
|
0.49 Percentage of CD marker cells
Standard Deviation 0.601
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; D15;S1;n=1,3,1,5,4,9
|
0.26 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.07 Percentage of CD marker cells
Standard Deviation 0.115
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
1.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.71 Percentage of CD marker cells
Standard Deviation 0.204
|
0.42 Percentage of CD marker cells
Standard Deviation 0.632
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; D15;S2n=0,0,1,0,0,0
|
—
|
—
|
0.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; D29; n=1,3,1,4,4,8
|
0.54 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.00 Percentage of CD marker cells
Standard Deviation 0.000
|
1.53 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.28 Percentage of CD marker cells
Standard Deviation 0.392
|
0.19 Percentage of CD marker cells
Standard Deviation 0.194
|
1.46 Percentage of CD marker cells
Standard Deviation 1.849
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; FU;n=1,2,0,3,1,4
|
0.04 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.29 Percentage of CD marker cells
Standard Deviation 0.410
|
—
|
0.18 Percentage of CD marker cells
Standard Deviation 0.267
|
0.09 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
0.20 Percentage of CD marker cells
Standard Deviation 0.189
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX244; USC;n=0,0,1,0,0,0
|
—
|
—
|
0.79 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
—
|
—
|
—
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; D1; pre; n=1,3,1,5,4,9
|
31.86 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.28 Percentage of CD marker cells
Standard Deviation 3.144
|
16.07 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
19.11 Percentage of CD marker cells
Standard Deviation 7.819
|
17.21 Percentage of CD marker cells
Standard Deviation 3.797
|
24.26 Percentage of CD marker cells
Standard Deviation 16.218
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; D1; 1h; n=1,3,1,5,4,9
|
22.75 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
20.32 Percentage of CD marker cells
Standard Deviation 2.902
|
11.93 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
18.27 Percentage of CD marker cells
Standard Deviation 9.233
|
14.21 Percentage of CD marker cells
Standard Deviation 3.682
|
22.37 Percentage of CD marker cells
Standard Deviation 17.894
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; D1; 6h; n=1,3,1,5,4,11
|
21.76 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
23.22 Percentage of CD marker cells
Standard Deviation 11.931
|
6.35 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
16.59 Percentage of CD marker cells
Standard Deviation 5.742
|
15.82 Percentage of CD marker cells
Standard Deviation 4.876
|
20.79 Percentage of CD marker cells
Standard Deviation 12.726
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; D2; n=0,0,1,2,0,1
|
—
|
—
|
9.47 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
10.31 Percentage of CD marker cells
Standard Deviation 3.946
|
—
|
11.46 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
|
Percentage of Cluster of Differentiation (CD) Marker
CDX245; D8; n=1,3,0,5,4,8
|
22.00 Percentage of CD marker cells
Standard Deviation NA
Standard deviation could not be calculated as a single participant was analyzed at the specified time point.
|
24.56 Percentage of CD marker cells
Standard Deviation 5.547
|
—
|
19.37 Percentage of CD marker cells
Standard Deviation 10.290
|
20.23 Percentage of CD marker cells
Standard Deviation 1.977
|
28.88 Percentage of CD marker cells
Standard Deviation 21.510
|
Adverse Events
GSK2849330 1.4 mg/kg Weekly
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
GSK2849330 3 mg/kg Every 2 Weeks
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
GSK2849330 3 mg/kg Weekly
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
GSK2849330 10 mg/kg Every 2 Weeks
Serious events: 1 serious events
Other events: 5 other events
Deaths: 0 deaths
GSK2849330 30 mg/kg Every 2 Weeks
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
GSK2849330 30 mg/kg Weekly
Serious events: 3 serious events
Other events: 14 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 participants at risk
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 participants at risk
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 participants at risk
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 participants at risk
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 participants at risk
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 participants at risk
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Escherichia sepsis
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
Other adverse events
| Measure |
GSK2849330 1.4 mg/kg Weekly
n=1 participants at risk
Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
|
GSK2849330 3 mg/kg Every 2 Weeks
n=3 participants at risk
Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 3 mg/kg Weekly
n=2 participants at risk
Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
|
GSK2849330 10 mg/kg Every 2 Weeks
n=5 participants at risk
Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
|
GSK2849330 30 mg/kg Every 2 Weeks
n=4 participants at risk
Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
|
GSK2849330 30 mg/kg Weekly
n=14 participants at risk
Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).
|
|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Diarrhoea
|
100.0%
1/1 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
100.0%
3/3 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
40.0%
2/5 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
75.0%
3/4 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
64.3%
9/14 • Number of events 12 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
66.7%
2/3 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
28.6%
4/14 • Number of events 7 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
40.0%
2/5 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
28.6%
4/14 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
75.0%
3/4 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Constipation
|
100.0%
1/1 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Abdominal distension
|
100.0%
1/1 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
2/4 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Oesophageal obstruction
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Dyspepsia
|
100.0%
1/1 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Gingival pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Impaired gastric emptying
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Gastrointestinal disorders
Tongue coated
|
100.0%
1/1 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Fatigue
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
66.7%
2/3 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
100.0%
2/2 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
40.0%
2/5 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
2/4 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
71.4%
10/14 • Number of events 12 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Chest pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Chills
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Malaise
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Oedema peripheral
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Chest discomfort
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Discomfort
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Influenza like illness
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Mucosal inflammation
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
General disorders
Pyrexia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
40.0%
2/5 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
21.4%
3/14 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
28.6%
4/14 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Investigations
Weight decreased
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
28.6%
4/14 • Number of events 5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
21.4%
3/14 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Skin fissures
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Onychomadesis
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Psoriasis
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
100.0%
1/1 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
21.4%
3/14 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Muscle twitching
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Nervous system disorders
Headache
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
66.7%
2/3 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
100.0%
2/2 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Nervous system disorders
Tremor
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Nervous system disorders
Cough
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
40.0%
2/5 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
2/4 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
21.4%
3/14 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Metabolism and nutrition disorders
Hypophagia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Metabolism and nutrition disorders
Increased appetite
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Lung infection
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Cystitis
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Otitis externa
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Paronychia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Infections and infestations
Viral infection
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Vascular disorders
Hypertension
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Vascular disorders
Vena cava thrombosis
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
21.4%
3/14 • Number of events 3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Eye disorders
Vision blurred
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Eye disorders
Glaucoma
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Eye disorders
Retinal haemorrhage
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
20.0%
1/5 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
50.0%
1/2 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
25.0%
1/4 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
14.3%
2/14 • Number of events 2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Reproductive system and breast disorders
Vulvovaginal pruritus
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
33.3%
1/3 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/14 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Cardiac disorders
Aortic valve disease
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
|
Product Issues
Device dislocation
|
0.00%
0/1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/3 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/2 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/5 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
0.00%
0/4 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
7.1%
1/14 • Number of events 1 • AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER